<SEC-DOCUMENT>0001213900-24-113500.txt : 20241230
<SEC-HEADER>0001213900-24-113500.hdr.sgml : 20241230
<ACCEPTANCE-DATETIME>20241230163007
ACCESSION NUMBER:		0001213900-24-113500
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20241227
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241230
DATE AS OF CHANGE:		20241230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			180 Life Sciences Corp.
		CENTRAL INDEX KEY:			0001690080
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813832378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38105
		FILM NUMBER:		241590199

	BUSINESS ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306
		BUSINESS PHONE:		650-507-0669

	MAIL ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KBL MERGER CORP. IV
		DATE OF NAME CHANGE:	20161115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0226200-8k_180life.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ATNF="http://180life.com/20241227">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_ATNF_180life.com_20241227 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20241227_20241227 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001690080 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000004" name="dei:EntityCentralIndexKey">0001690080</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="atnf-20241227.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-12-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-27</xbrli:startDate>
        <xbrli:endDate>2024-12-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-272024-12-27_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-27</xbrli:startDate>
        <xbrli:endDate>2024-12-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-272024-12-27_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-27</xbrli:startDate>
        <xbrli:endDate>2024-12-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>FORM&#160;<span id="xdx_906_edei--DocumentType_c20241227__20241227_zhpZIjfJnN3g"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>PURSUANT TO SECTION
13 OR 15(d) OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>SECURITIES EXCHANGE
ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">Date of Report (Date of
earliest event reported):&#160;<span id="xdx_905_edei--DocumentPeriodEndDate_c20241227__20241227_z490cmQ3bSTb"><ix:nonNumeric contextRef="AsOf2024-12-27" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">December 27, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityRegistrantName_c20241227__20241227_zRMunqdc6ef"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000011" name="dei:EntityRegistrantName">180 LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">(Exact Name of Registrant
as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20241227__20241227_ztiya6mzbjR4"><ix:nonNumeric contextRef="AsOf2024-12-27" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20241227__20241227_zJGtQSnqhn13"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000013" name="dei:EntityFileNumber">001-38105</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20241227__20241227_zzsFOqvSoPLk"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000014" name="dei:EntityTaxIdentificationNumber">90-1890354</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction<br/>
of Incorporation)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20241227__20241227_zhD9uTRicvmj"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000015" name="dei:EntityAddressAddressLine1">3000 El Camino Real</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20241227__20241227_zkLPPrq7HVqf"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000016" name="dei:EntityAddressAddressLine2">Bldg. 4</ix:nonNumeric></span>,&#160;<span id="xdx_903_edei--EntityAddressAddressLine3_c20241227__20241227_zlD3sbXWE5sh"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000017" name="dei:EntityAddressAddressLine3">Suite 200</ix:nonNumeric></span><br/> <span id="xdx_901_edei--EntityAddressCityOrTown_c20241227__20241227_zewIXirwalDh"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000018" name="dei:EntityAddressCityOrTown">Palo Alto</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressStateOrProvince_c20241227__20241227_z7hA6Wyekqx6"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000019" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20241227__20241227_zfEgLGvb3kgd"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000020" name="dei:EntityAddressPostalZipCode">94306</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Registrant&#8217;s telephone
number, including area code:&#160;<b><span style="text-decoration: underline">(<span id="xdx_90B_edei--CityAreaCode_c20241227__20241227_zSVOo5eHGIY3"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000021" name="dei:CityAreaCode">650</ix:nonNumeric></span>)&#160;<span id="xdx_903_edei--LocalPhoneNumber_c20241227__20241227_zjAV9E3UXIrb"><ix:nonNumeric contextRef="AsOf2024-12-27" id="Fact000022" name="dei:LocalPhoneNumber">507-0669</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Check the appropriate&#160;box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see&#160;</i>General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.15pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--WrittenCommunications_c20241227__20241227_zyxax2AAdLX1"><ix:nonNumeric contextRef="AsOf2024-12-27" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--SolicitingMaterial_c20241227__20241227_zGE36Utl6ct1"><ix:nonNumeric contextRef="AsOf2024-12-27" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementTenderOffer_c20241227__20241227_zVsDxITixEE"><ix:nonNumeric contextRef="AsOf2024-12-27" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20241227__20241227_z5ifDCiUvVh9"><ix:nonNumeric contextRef="AsOf2024-12-27" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e 4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Securities registered
pursuant to Section 12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20241227__20241227__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zh4cMJztb5a"><ix:nonNumeric contextRef="From2024-12-272024-12-27_custom_CommonStockParValue0.0001PerShareMember" id="Fact000027" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20241227__20241227__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_z8dfG3CRdsS"><ix:nonNumeric contextRef="From2024-12-272024-12-27_custom_CommonStockParValue0.0001PerShareMember" id="Fact000028" name="dei:TradingSymbol">ATNF</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The
    <span id="xdx_905_edei--SecurityExchangeName_c20241227__20241227__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zGjFixQZe0V"><ix:nonNumeric contextRef="From2024-12-272024-12-27_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>&#160;Stock Market LLC</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20241227__20241227__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zwmRVkuG8iyb"><ix:nonNumeric contextRef="From2024-12-272024-12-27_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000030" name="dei:Security12bTitle">Warrants to purchase shares of Common Stock</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20241227__20241227__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zSoTMXFdMrCg"><ix:nonNumeric contextRef="From2024-12-272024-12-27_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000031" name="dei:TradingSymbol">ATNFW</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The
    <span id="xdx_90A_edei--SecurityExchangeName_c20241227__20241227__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zF4gRLO8axpb"><ix:nonNumeric contextRef="From2024-12-272024-12-27_custom_WarrantsToPurchaseSharesOfCommonStockMember" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>&#160;Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)&#160;or
Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Emerging growth company&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20241227__20241227_zT0ba50BzZl6"><ix:nonNumeric contextRef="AsOf2024-12-27" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a)&#160;of the Exchange Act.&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"><span style="font-size: 10pt">&#160;</span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01 Entry into a Material Definitive
Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
December 27, 2024, 180 Life Sciences Corp. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) entered into a Securities Purchase Agreement (the &#8220;<span style="text-decoration: underline">Purchase
Agreement</span>&#8221;) with certain accredited investors (the &#8220;<span style="text-decoration: underline">Investors</span>&#8221;). Pursuant to the terms of the Purchase Agreement,
the Company agreed to sell, in a registered direct offering, an aggregate of 1,200,000 shares (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;) of the
Company&#8217;s common stock (&#8220;<span style="text-decoration: underline">Common Stock</span>&#8221;) and, in a concurrent private placement, warrants (the &#8220;<span style="text-decoration: underline">Purchase
Warrants</span>&#8221;) to purchase up to 1,200,000 shares of Common Stock (the shares of Common Stock issuable upon exercise of the Purchase
Warrants, the &#8220;<span style="text-decoration: underline">Purchase Warrant Shares</span>&#8221;). The&#160;<span style="background-color: white">combined purchase price&#160;</span>per
Share and Purchase Warrant is $2.41.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Purchase Warrants are immediately exercisable on their grant date and will expire five and a half years following the initial exercise
date at an exercise price of $2.28 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to a placement agency
agreement (the &#8220;<span style="text-decoration: underline">Placement Agency Agreement</span>&#8221;) dated as of December 27, 2024, between the Company and Maxim Group LLC
(the &#8220;<span style="text-decoration: underline">Placement Agent</span>&#8221;), the Company engaged the Placement Agent to act as the Company&#8217;s sole placement agent
in connection with the registered direct offering. Pursuant to the Placement Agency Agreement, the Company agreed to pay the Placement
Agent a cash fee equal to seven percent (7.0%) of the gross proceeds received by the Company from the sale of the Shares and Warrants
and will reimburse the Placement Agent for certain of its expenses in an aggregate amount up to $50,000. The Placement Agency Agreement
contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations
of the Company and the Placement Agent, including for liabilities under the Securities Act of 1933, as amended, other obligations of the
parties, and termination provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registered direct offering
is expected to close on or about December 30, 2024, subject to the satisfaction of customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company has agreed to file a registration statement under the Act with the SEC, covering the resale of the Warrant Shares within 30 calendar
days following the date of the Purchase Agreement and to use commercially reasonable efforts to cause the registration statement to be
declared effective by the SEC within 91 days following the closing of the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
net proceeds to the Company from the registered direct offering and concurrent private placement, after deducting the placement agent&#8217;s
fees and expenses and the Company&#8217;s offering expenses are expected to be approximately $2.6 million. The Company intends to use
the net proceeds from the transactions for working capital and general corporate purposes, which may include operationalizing and developing
our recently acquired Technology Gaming Platform and capital expenditures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Shares (but not the Purchase Warrants or the Purchase Warrant Shares) were offered and sold by the Company pursuant to a prospectus supplement,
dated as of December 30, 2024, which was filed with the Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;) in connection
with a takedown from the Company&#8217;s effective shelf registration statement on Form S-3, which was initially filed with the SEC on
June 3, 2022, and subsequently declared effective on June 24, 2024 (File No. 333-265416).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
forms of the Placement Agency Agreement, Purchase Agreement, the Purchase Warrant are filed as Exhibits 1.1, 10.1 and 4.1, respectively,
to this Current Report on Form 8-K. The foregoing summaries of the terms of these documents are subject to, and qualified in their entirety
by, such documents, which are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
legal opinion and consent of The Loev Law Firm, PC relating to the Shares is filed as Exhibit 5.1 to this Current Report on Form 8-K and
is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, pursuant to
certain &#8220;<span style="text-decoration: underline">lock-up</span>&#8221; agreements (each, a &#8220;<span style="text-decoration: underline">Lock-Up
Agreement</span>&#8221;) that were required to be entered into as a condition to the closing of the Purchase Agreement, our
officers, directors and holders of our Series B Preferred Stock have agreed to not sell or transfer any shares of Common Stock,
subject to certain customary exceptions, for a period of 30 days from December 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
information contained above in Item 1.01 related to the Purchase Warrants and the Purchase Warrant Shares is hereby incorporated by reference
into this Item 3.02. The Purchase Warrants and Purchase Warrant Shares are being sold and issued without registration under the Securities
Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities
Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors,
and in reliance on similar exemptions under applicable state laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
maximum of 1,200,000 shares of Common Stock are issuable upon exercise of the Purchase Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 27, 2024 the Company
issued a press release regarding the registered direct offering. A copy of the press release is attached as <span style="text-decoration: underline">Exhibit 99.1</span> to this
Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d)&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 9%"><span style="font-size: 10pt">1.1</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 90%"><a href="ea022620001ex1-1_180life.htm"><span style="font-size: 10pt">Placement Agency Agreement by and between the Company and Maxim Group LLC, dated December 27, 2024</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><a href="ea022620001ex4-1_180life.htm"><span style="font-size: 10pt">Form of Common Stock Purchase Warrant (December 2024 Offering)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">5.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><a href="ea022620001ex5-1_180life.htm"><span style="font-size: 10pt">Opinion of The Loev Law Firm, PC</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.1+</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><a href="ea022620001ex10-1_180life.htm"><span style="font-size: 10pt">Form of&#160;Securities Purchase Agreement</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">23.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><a href="ea022620001ex5-1_180life.htm"><span style="font-size: 10pt">Consent of The Loev Law Firm, PC (included in Exhibit 5.1)</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">99.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><a href="ea022620001ex99-1_180life.htm"><span style="font-size: 10pt">Press Release dated December 27, 2024</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">+</td><td style="text-align: justify">Pursuant to Item 601(a)(5) of Regulation S-K, schedules have
been omitted and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b></b></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Date: December 30, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>180 LIFE SCIENCES CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><i>/s/ Blair Jordan</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="width: 31%"><span style="font-size: 10pt">Blair Jordan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Interim Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kdFqwjAUhp/AdziUXYqmQRF6txUnY7oVFbfbrD2dwTannKROH2lvuTRV5sUWAuFwzvf//yFRNIwW9KgrZHh/WC9hi3VTKYewxhIZTY5+In16TsC/a/zU1rEyLpRXMCXPoGemIznJfSOMHrXFIoFYjuVsLCcgZsl0AtkqGnT9lEypCzROqwqUKSBjalijU3zuFbbqRIbqc7DaIVtNxsuNRN/+BiliCS90VF/EBwvLZRoNhuEMogVT2/ip+cmh6UiYV1h7O9vTvzekyVvrqE7eFHfL2S1lLed7ZXGzV4z2tfQr1mQ2jvLDCusPZA/FQspY3F/yXFlwBM2FBhtwoBJ6AQgKfzjf6GeKd6pqUYyEEHGGHDL843orO4RGMRw7Fu56Ghr/PSHE1fMHei6WDg== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea022620001ex1-1_180life.htm
<DESCRIPTION>PLACEMENT AGENCY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>PLACEMENT AGENCY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">December 27, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Blair Jordan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interim Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">180 Life Sciences Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">3000 El Camino Real, Bldg. 4,
Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Palo Alto, CA 94306</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dear Mr. Jordan:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This agreement (the &ldquo;<U>Agreement</U>&rdquo;)
constitutes the agreement between Maxim Group LLC (&ldquo;<U>Maxim</U>&rdquo; or the &ldquo;<U>Placement Agent</U>&rdquo;) and 180 Life
Sciences Corp., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), that Maxim shall serve as the exclusive placement agent for
the Company, on a &ldquo;commercially reasonable efforts&rdquo; basis, in connection with the proposed placement (the &ldquo;<U>Placement</U>&rdquo;)
of (i) registered shares (the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s common stock, par value $0.0001 (the &ldquo;<U>Common
Stock</U>&rdquo;) and (ii) warrants to purchase shares of Common Stock (the &ldquo;<U>Warrants</U>&rdquo;, and the shares issuable upon
exercise of the Warrants, the &ldquo;<U>Warrant Shares</U>&rdquo; and the Shares, Warrants and Warrant Shares, collectively, the &ldquo;<U>Securities</U>&rdquo;).
The terms of the Placement shall be mutually agreed upon by the Company, Maxim and the purchasers of the Securities (each, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively, the &ldquo;<U>Purchasers</U>&rdquo;) and nothing herein constitutes that Maxim would have the power or authority to
bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and
the documents executed and delivered by the Company and the Purchasers in connection with the Placement, including but not limited to
the Purchase Agreement and the Warrants shall be collectively referred to herein as the &ldquo;<U>Transaction Documents</U>.&rdquo; The
date of the closing of the Placement shall be referred to herein as a &ldquo;<U>Closing Date</U>.&rdquo; The Company expressly acknowledges
and agrees that Maxim&rsquo;s obligations hereunder are on a commercially reasonable efforts basis only and that the execution of this
Agreement does not constitute a legal or binding commitment by Maxim to purchase the Securities or introduce the Company to investors
and does not ensure the successful placement of the Securities or any portion thereof or the success of Maxim with respect to securing
any other financing on behalf of the Company. The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers
on its behalf in connection with the Placement. The sale of the Securities to any Purchaser will be evidenced by a securities purchase
agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;) between the Company and such Purchaser in a form reasonably acceptable to the
Company and Maxim. Capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 1.</U><FONT STYLE="text-decoration: none">&nbsp;</FONT><U>REPRESENTATIONS
AND WARRANTIES OF THE COMPANY; COVENANTS OF THE COMPANY</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;<U>Representations
of the Company</U>. Each of the representations and warranties (together with any related disclosure schedules thereto) and covenants
made by the Company to the Purchasers in the Purchase Agreement in connection with the Placement is hereby incorporated herein by reference
into this Agreement (as though fully restated herein) and is, as of the date of this Agreement and as of the Closing Date, hereby made
to, and in favor of, the Placement Agent. In addition to the foregoing, the Company represents and warrants that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.&nbsp;Assuming
the accuracy of the Purchasers&rsquo; representations and warranties set forth in the Purchase Agreement, no registration under the Securities
Act is required for the offer and sale of the Warrants or the shares issuable upon exercise of the Warrants by the Company to the Purchasers
as contemplated thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.&nbsp;There
are no affiliations with any FINRA member firm among the Company&rsquo;s officers, directors or, to the knowledge of the Company, any ten percent
(10.0%) or greater stockholder of the Company, except as set forth in the Registration Statement and the other documents the Company has
filed or furnished with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;<U>Covenants
of the Company</U>. The Company has delivered, or will as promptly as practicable deliver, to the Placement Agent materially complete
conformed copies of the Registration Statement and of each consent and certificate of experts, as applicable, filed as a part thereof,
and conformed copies of the Registration Statement (without exhibits), the Base Prospectus, the Time of Sale Prospectus and the Prospectus
Supplement, as amended or supplemented, in such quantities and at such places as the Placement Agent reasonably requests. Neither the
Company nor any of its directors and officers has distributed and none of them will distribute, prior to the Closing Date, any offering
material in connection with the offering and sale of the Securities pursuant to the Placement other than the Base Prospectus, the Time
of Sale Prospectus, the Prospectus Supplement, the Registration Statement, copies of the documents incorporated by reference therein and
any other materials permitted by the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 2</U>. &nbsp;<U>REPRESENTATIONS
OF THE PLACEMENT AGENT</U>. The Placement Agent represents and warrants that it (i) is a member in good standing of FINRA, (ii) is registered
as a broker/dealer under the Exchange Act, (iii) is licensed as a broker/dealer under the laws of the states applicable to the offers
and sales of the Securities by such Placement Agent, (iv) is and will be a body corporate validly existing under the laws of its place
of incorporation, and (v) has full power and authority to enter into and perform its obligations under this Agreement. The Placement Agent
will immediately notify the Company in writing of any change in its status as such. The Placement Agent covenants that it will use its
reasonable best efforts to conduct the Placement hereunder in compliance with the provisions of this Agreement and the requirements of
applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 3</U>. &nbsp;<U>COMPENSATION</U>.
In consideration of the services to be provided for hereunder, the Company shall pay to the Placement Agent or their respective designees
their pro rata portion (based on the Securities placed) of the following compensation with respect to the Securities which they are placing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;A
cash fee (the &ldquo;<B>Cash Fee</B>&rdquo;) equal to an aggregate of seven percent (7.0%) of the aggregate gross proceeds raised in the
Placement. The Cash Fee shall be paid at the closing of the Placement (the &ldquo;<B>Closing</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;Subject
to compliance with FINRA Rule 5110(f)(2)(D), the Company also agrees, in case of Closing of the Placement, to reimburse the Placement
Agent for all travel and other out-of-pocket expenses incurred, including the reasonable fees, costs and disbursements of its legal counsel,
in an amount not to exceed an aggregate of $50,000 (inclusive of any advances received by the Placement Agent from the Company). The Company
will reimburse Placement Agent directly upon the Closing of the Placement from the gross proceeds raised in the Placement. In the event
that this Agreement shall terminate prior to the consummation of the Placement, Maxim shall nevertheless still be entitled to reimbursement
for its actual expenses; provided, however, that such expenses shall not exceed $25,000, in the aggregate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;The
Placement Agent reserves the right to reduce any item of its compensation or adjust the terms thereof as specified herein in the event
that a determination shall be made by FINRA to the effect that such Placement Agent&rsquo;s aggregate compensation is in excess of FINRA
rules or that the terms thereof require adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 4</U>.&nbsp;<U>INDEMNIFICATION</U>.
The Company agrees to the indemnification and other agreements set forth in the Indemnification Provisions (the &ldquo;<B>Indemnification</B>&rdquo;)
attached hereto as <U>Addendum A</U>, the provisions of which are incorporated herein by reference and shall survive the termination or
expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 5</U>.&nbsp;<U>ENGAGEMENT
TERM</U>. The Placement Agent&rsquo;s engagement hereunder shall be until the final closing date of the Placement (the period of time
during which this Agreement remains in effect is referred to herein as the &ldquo;<B>Term</B>&rdquo;). Notwithstanding anything to the
contrary contained herein, the provisions concerning confidentiality and indemnification and contribution contained herein and the Company&rsquo;s
obligations contained in the Indemnification Provisions will survive any expiration or termination of this Agreement. The Placement Agent
agrees not to use any confidential information concerning the Company provided to the Placement Agent by the Company for any purposes
other than those contemplated under this Agreement. In addition, if the Company completes any financing of equity, equity-linked, convertible
or debt or other capital raising activity with, or receives any proceeds from, any of the investors who were contacted or introduced to
the Company by the Placement Agent during the Term (the &ldquo;<B>PA Investors</B>&rdquo;) within twelve (12) months after the Closing
or termination of this Agreement (other than for &ldquo;Cause&rdquo;), then the Company will pay to the Placement Agent upon the closing
of such financing as a financing participation right the compensation set forth in Section 3(A) above with respect to the funds received
by the Company from the PA Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 6</U>.&nbsp;<U>PLACEMENT
AGENT INFORMATION</U>. The Company agrees that any information or advice rendered by the Placement Agent in connection with this engagement
is for the confidential use of the Company only in their evaluation of the Placement and, except as otherwise required by law, the Company
will not disclose or otherwise refer to the advice or information in any manner without the Placement Agent&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 7</U>.&nbsp;<U>NO
FIDUCIARY RELATIONSHIP</U>. This Agreement does not create, and shall not be construed as creating rights enforceable by any person or
entity not a party hereto, except those entitled hereto by virtue of the Indemnification Provisions hereof. The Company acknowledges and
agrees that the Placement Agent is not and shall not be construed as a fiduciary of the Company and shall have no duties or liabilities
to the equity holders or the creditors of the Company or any other person by virtue of this Agreement or the retention of such Placement
Agent hereunder, all of which are hereby expressly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 8</U>.&nbsp;<U>CLOSING</U>.
The obligations of the Placement Agent, and the closing of the sale of the Securities hereunder are subject to the accuracy, when made
and on the Closing Date, of the representations and warranties on the part of the Company and its subsidiaries contained herein and in
the Purchase Agreement, to the accuracy of the statements of the Company and its subsidiaries made in any certificates pursuant to the
provisions hereof, to the performance by the Company and its subsidiaries of their obligations hereunder, and to each of the following
additional terms and conditions, except as otherwise disclosed to and acknowledged and waived by the Placement Agent to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;No
stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings for that purpose shall
have been initiated or threatened by the Commission, and any request for additional information on the part of the Commission (to be included
in the Registration Statement, the Base Prospectus, the Prospectus Supplement or otherwise) shall have been complied with to the reasonable
satisfaction of the Placement Agent. Any filings required to be made by the Company in connection with the Placement shall have been timely
filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;The
Placement Agent shall not have discovered and disclosed to the Company on or prior to the Closing Date that the Registration Statement,
the Base Prospectus, the Prospectus Supplement or any amendment or supplement thereto contains an untrue statement of a fact which, in
the reasonable opinion of counsel for the Placement Agent, is material or omits to state any fact which, in the reasonable opinion of
such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;All
corporate proceedings and other legal matters incident to the authorization, form, execution, delivery and validity of each of this Agreement,
the Securities, the Registration Statement, the Base Prospectus and the Prospectus Supplement and all other legal matters relating to
this Agreement and the transactions contemplated hereby shall be reasonably satisfactory in all material respects to counsel for the Placement
Agent, and the Company shall have furnished to such counsel all documents and information that they may reasonably request to enable them
to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D.&nbsp;The
Placement Agent shall have received from outside counsel to the Company such counsel&rsquo;s written opinion, including without limitation
a negative assurance letter, addressed to the Placement Agent and the Purchasers and dated as of the Closing Date, in form and substance
reasonably satisfactory to the Placement Agent, the Purchasers, and Placement Agent&rsquo;s legal counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E.&nbsp;On
the Closing Date, the Placement Agent shall have received &ldquo;comfort&rdquo; letters from Marcum, LLP and M&amp;K CPAs, PLLC, or such
other independent registered public accounting firm of the Company as of such date, addressed to each of the Placement Agent and in the
form and substance satisfactory in all respects to the Placement Agent and Placement Agent&rsquo;s legal counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">F.&nbsp;On
the Closing Date, Placement Agent shall have received a certificate of the chief executive officer of the Company, dated, as applicable,
as of the date of such Closing, to the effect that, as of the date of this Agreement and as of the applicable date, the representations
and warranties of the Company contained herein and in the Purchase Agreement were and are accurate in all material respects, except for
such changes as are contemplated by this Agreement and except as to representations and warranties that were expressly limited to a state
of facts existing at a time prior to the applicable Closing Date, and that, as of the applicable date, the obligations to be performed
by the Company hereunder on or prior thereto have been fully performed in all material respects. If necessary, on the Closing Date, the
Placement Agent shall have received a certificate of the chief financial officer of the Company, dated, as applicable, as of the date
of such Closing, providing a customary certification as to such accounting or financial matters that are included or incorporated by reference
in the Registration Statement or the Prospectus Supplement that Marcum and M&amp;K are unable to provide assurances on in the letter contemplated
by Section 8(E) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">G.&nbsp;On
the Closing Date, Placement Agent shall have received a certificate of the Secretary of the Company, dated, as applicable, as of the date
of such Closing, certifying to the organizational documents, good standing in the state of incorporation of the Company and board resolutions
relating to the Placement of the Securities from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">H.&nbsp;Neither
the Company nor any of its subsidiaries (i) shall have sustained since the date of the latest audited financial statements included or
incorporated by reference in the Registration Statement, the Base Prospectus and the Prospectus Supplement, any loss or interference with
its business from fire, explosion, flood, terrorist act or other calamity, whether or not covered by insurance, or from any labor dispute
or court or governmental action, order or decree, otherwise than as set forth in or contemplated by the Registration Statement, the Base
Prospectus and the Prospectus Supplement, (ii) since such date there shall not have been any change in the capital stock or long-term
debt of the Company or any of its subsidiaries or any change, or any development involving a prospective change, in or affecting the business,
general affairs, management, financial position, stockholders&rsquo; equity, results of operations or prospects of the Company and its subsidiaries,
otherwise than as set forth in or contemplated by the Registration Statement, the Base Prospectus and the Prospectus Supplement, and (iii)
since such date there shall not have been any new or renewed inquiries by the Commission, FINRA or any other regulatory body regarding
the Company, the effect of which, in any such case described in clause (i), (ii) or (iii), is, in the judgment of the Placement Agent,
so material and adverse as to make it impracticable or inadvisable to proceed with the sale or delivery of the Securities on the terms
and in the manner contemplated by the Base Prospectus, Time of Sale Prospectus and Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">I.&nbsp;The
Common Stock is registered under the Exchange Act and, as of the Closing Date, the Shares and the Warrant Shares shall be listed and admitted
and authorized for trading on the Trading Market or other applicable U.S. national exchange, or an application for such listing shall
have been submitted to the Trading Market, and satisfactory evidence of such action shall have been provided to the Placement Agent. The
Company shall have taken no action designed to, or likely to have the effect of terminating the registration of the Common Stock under
the Exchange Act or delisting or suspending from trading the Common Stock from the Trading Market or other applicable U.S. national exchange,
nor, except as disclosed in the Base Prospectus and Prospectus Supplement, has the Company received any information suggesting that the
Commission or the Trading Market or other U.S. applicable national exchange is contemplating terminating such registration or listing,
except as disclosed in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">J.&nbsp;No
action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental
agency or body which would, as of the Closing Date, prevent the issuance or sale of the Securities or materially and adversely affect
or potentially and adversely affect the business or operations of the Company; and no injunction, restraining order or order of any other
nature by any federal or state court of competent jurisdiction shall have been issued as of the Closing Date which would prevent the issuance
or sale of the Securities or materially and adversely affect or potentially and adversely affect the business or operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">K.&nbsp;The
Company shall have prepared and filed with the Commission a Form 8-K with respect to the Placement, including as an exhibit thereto this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">L.&nbsp;The
Company shall have entered into a Purchase Agreement with each of the Purchasers and such agreements shall be in full force and effect
and shall contain representations, warranties and covenants of the Company as agreed between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">M.&nbsp;Prior
to the Closing Date, the Company shall have furnished to the Placement Agent such further information, certificates and documents as the
Placement Agent may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the conditions specified
in this Section 8 shall not have been fulfilled when and as required by this Agreement, or if any of the certificates, opinions, written
statements or letters furnished to the Placement Agent or to Placement Agent&rsquo;s counsel pursuant to this Section 8 shall not be reasonably
satisfactory in form and substance to the Placement Agent and to Placement Agent&rsquo;s legal counsel, all obligations of the Placement
Agent hereunder may be cancelled by the Placement Agent at, or at any time prior to, the consummation of the Closing. Notice of such cancellation
shall be given to the Company in writing or orally. Any such oral notice shall be confirmed promptly thereafter in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 9</U>.&nbsp; <FONT STYLE="text-transform: uppercase"><U>SUBSEQUENT
EQUITY SALES.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;<FONT STYLE="font-size: 10pt">From
the date hereof until thirty (30) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any
agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file
any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or the resale registration statement
to be filed pursuant to Section 4.18 of the Purchase Agreement or amendments to that certain registration statement on Form S-1 (File
No. 333-283265) or filing a registration statement on Form S-8 in connection with any employee benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;<FONT STYLE="font-size: 10pt">From
the date hereof until thirty (30) days after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement
to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units
thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company
(i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to
receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based
upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such
debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after
the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related
to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities
at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether
such agreement is subsequently canceled, provided, however, </FONT>securities sold pursuant to t<FONT STYLE="font-size: 10pt">he registration
statement on Form S-1 (File No. 333-283265) shall not be deemed a Variable Rate Transaction. The Placement Agent shall be entitled to
obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect
damages. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, this Section 9(c) shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an
Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 10</U>.&nbsp;<U>GOVERNING
LAW</U>. This Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements
made and to be performed entirely in such State, without regard to the conflicts of laws principles thereof. This Agreement may not be
assigned by either party without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit
of the parties hereto, and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising
under this Agreement or any transaction or conduct in connection herewith is waived. Any dispute arising under this Agreement may be brought
into the courts of the State of New York or into the federal court located in New York, New York and, by execution and delivery of this
Agreement, the Company hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of aforesaid
courts. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The Company
agrees that a final judgment in any such action, proceeding or counterclaim brought in any such court shall be conclusive and binding
upon the Company and may be enforced in any other courts to the jurisdiction of which the Company is or may be subject, by suit upon such
judgment. If either party shall commence an action or proceeding to enforce any provisions of a Transaction Document, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorney&rsquo;s fees and other costs and expenses incurred
with the investigation, preparation and prosecution of such action or proceeding. This paragraph shall survive any termination of this
Agreement, in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 11</U>.&nbsp;<U>ENTIRE
AGREEMENT/MISC</U>. This Agreement (including the attached Indemnification Provisions) embodies the entire agreement and understanding
between the parties hereto, and supersedes all prior agreements and understandings, relating to the subject matter hereof. Notwithstanding
anything herein to the contrary, the Engagement Agreement between the Company and Maxim, dated November 22, 2024, shall continue to be
effective and the terms therein shall continue to survive and be enforceable by the Placement Agent in accordance with its terms (including,
for the avoidance of doubt, the indemnification provisions included therein). This Agreement may be executed in two or more counterparts,
each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This
Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied)
may be waived unless waived in writing by each party whom the condition is meant to benefit. Section headings herein are for the convenience
of the parties only and shall not affect the construction or interpretation of this Agreement. If any provision of this Agreement is determined
to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect or any other provision
of this Agreement, which will remain in full force and effect. This Agreement may not be amended or otherwise modified or waived except
by an instrument in writing signed by both Placement Agent and the Company. The representations, warranties, agreements and covenants
contained herein shall survive the closing of the Placement and delivery of the Securities. This Agreement may be executed in two or more
counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts
have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart.
In the event that any signature is delivered by facsimile transmission or a .pdf format file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile
or .pdf signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt"><U>SECTION 12</U>.<U>&nbsp;CONFIDENTIALITY</U>.
The Placement Agent (i) will keep the Confidential Information (as such term is defined below) confidential and will not (except as required
by applicable law or stock exchange requirement, regulation or legal process (&ldquo;<B>Legal Requirement</B>&rdquo;), without the Company&rsquo;s
prior written consent, disclose to any person any Confidential Information, and (ii) will not use any Confidential Information other than
in connection with the Placement. The Placement Agent further agrees, severally and not jointly, to disclose the Confidential Information
only to its Representatives (as such term is defined below) who need to know the Confidential Information for the purpose of the Placement,
and who are informed by the Placement Agent of the confidential nature of the Confidential Information. The term &ldquo;<B>Confidential
Information</B>&rdquo; shall mean, all confidential, proprietary and non-public information (whether written, oral or electronic communications)
furnished by the Company to a Placement Agent or its Representatives in connection with such Placement Agent&rsquo;s evaluation of the
Placement. The term &ldquo;<B>Confidential Information</B>&rdquo; will not, however, include information which (i) is or becomes publicly
available other than as a result of a disclosure by a Placement Agent or its Representatives in violation of this Agreement, (ii) is or
becomes available to a Placement Agent or any of its Representatives on a non-confidential basis from a third-party, (iii) is known to
a Placement Agent or any of its Representatives prior to disclosure by the Company or any of its Representatives, or (iv) is or has been
independently developed by a Placement Agent and/or the Representatives without use of any Confidential Information furnished to it by
the Company. The term &ldquo;Representatives&rdquo; shall mean the Placement Agent&rsquo;s directors, board committees, officers, employees,
financial advisors, attorneys and accountants. This provision shall be in full force until the earlier of (a) the date that the Confidential
Information ceases to be confidential and (b) two (2) years from the date hereof. Notwithstanding any of the foregoing, in the event that
the Placement Agent or any of their respective Representatives are required by Legal Requirement to disclose any of the Confidential Information,
such Placement Agent and their respective Representatives will furnish only that portion of the Confidential Information which such Placement
Agent or their respective Representative, as applicable, is required to disclose by Legal Requirement as advised by counsel, and will
use reasonable efforts to obtain reliable assurance that confidential treatment will be accorded the Confidential Information so disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 13</U>.<I>&nbsp;</I><U>NOTICES</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is sent to the email address
specified on the signature pages attached hereto prior to 6:30 p.m. (New York City time) on a business day, (b) the next business day
after the date of transmission, if such notice or communication is sent to the email address on the signature pages attached hereto on
a day that is not a business day or later than 6:30 p.m. (New York City time) on any business day, (c) the third business day following
the date of mailing, if sent by U.S. internationally recognized air courier service, or (d) upon actual receipt by the party to whom such
notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 14</U>.&nbsp;<FONT STYLE="text-transform: uppercase"><U>Press
Announcements</U></FONT>. The Company agrees that the Placement Agent shall, from and after any Closing, have the right to reference the
Placement and the Placement Agent&rsquo;s role in connection therewith in the Placement Agent&rsquo;s marketing materials and on its website
and to place advertisements in financial and other newspapers and journals, in each case at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[<I>The remainder of this page
has been intentionally left blank.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please confirm that the foregoing
correctly sets forth our agreement by signing and returning to Maxim the enclosed copy of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Maxim GROUP LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Ritesh Veera</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: </FONT></TD>
    <TD STYLE="width: 31%">Ritesh Veera</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:&nbsp;</FONT></TD>
    <TD>Co-Head of investment Banking</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%; text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Address for
    notice:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">300 Park Avenue</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">New York, NY 10022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attention: James Siegel, General
    Counsel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email: jsiegel@maximgrp.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Accepted and Agreed to as of</FONT><TD STYLE="text-indent: 0in; font-size: 10pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the date first written above:</FONT></TD>
    <TD STYLE="text-indent: 0in; font-size: 10pt"></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-indent: 0in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>180
    Life sciences corp.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-indent: 0in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Blair Jordan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-size: 10pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in; font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in; font-size: 10pt; width: 31%"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Blair Jordan</FONT></TD><TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-size: 10pt"></TD>
    <TD STYLE="text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: </FONT></TD>
    <TD STYLE="text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interim Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Address for notice</U>:</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">180 Life Sciences Corp.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3000 El Camino Real, Bldg. 4, Suite 200 Palo Alto, CA 94306</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email: blair.jordan@highmontadvisors.com</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[<I>Signature Page to Placement
Agency Agreement Between </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><I>Maxim Group LLC and 180 Life
Sciences Corp.</I>]</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ADDENDUM A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><U>INDEMNIFICATION PROVISIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the engagement
of Maxim Group LLC (the &ldquo;Placement Agent&rdquo;) by 180 Life Sciences Corp. (the &ldquo;Company&rdquo;) pursuant to a placement
agency agreement dated as of the date hereof, between the Company and the Placement Agent, as it may be amended from time to time in writing
(the &ldquo;Agreement&rdquo;), the Company hereby agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;To
the extent permitted by law, the Company will indemnify the Placement Agent and its affiliates, directors, officers, employees and controlling
persons (within the meaning of Section 15 of the Securities Act of 1933, as amended, or Section 20 of the Securities Exchange Act of 1934,
as amended) against all losses, claims, damages, expenses and liabilities, as the same are incurred (including the reasonable fees and
expenses of counsel), relating to or arising out of its activities hereunder or pursuant to the Agreement, except, with regard to the
Placement Agent, to the extent that any losses, claims, damages, expenses or liabilities (or actions in respect thereof) are found in
a final judgment (not subject to appeal) by a court of law to have resulted primarily and directly from the Placement Agent&rsquo;s willful
misconduct or gross negligence in performing the services described herein, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;Promptly
after receipt by the Placement Agent of notice of any claim or the commencement of any action or proceeding with respect to which the
Placement Agent is entitled to indemnity hereunder, the Placement Agent will notify the Company in writing of such claim or of the commencement
of such action or proceeding, and the Company will assume the defense of such action or proceeding and will employ counsel reasonably
satisfactory to the Placement Agent and will pay the fees and expenses of such counsel. Notwithstanding the preceding sentence, the Placement
Agent will be entitled to employ counsel separate from counsel for the Company and from any other party in such action if counsel for
the Placement Agent reasonably determines that it would be inappropriate under the applicable rules of professional responsibility for
the same counsel to represent both the Company and the Placement Agent. In such event, the reasonable fees and disbursements of no more
than one such separate counsel will be paid by the Company. The Company will have the exclusive right to settle the claim or proceeding
provided that the Company will not settle any such claim, action or proceeding without the prior written consent of the Placement Agent,
which will not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;The
Company agrees to notify the Placement Agent promptly of the assertion against it or any other person of any claim or the commencement
of any action or proceeding relating to a transaction contemplated by the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;If
for any reason the foregoing indemnity is unavailable to the Placement Agent or insufficient to hold the Placement Agent harmless, then
the Company shall contribute to the amount paid or payable by the Placement Agent, as the case may be, as a result of such losses, claims,
damages or liabilities in such proportion as is appropriate to reflect not only the relative benefits received by the Company on the one
hand, and the Placement Agent on the other, but also the relative fault of the Company on the one hand and the Placement Agent on the
other that resulted in such losses, claims, damages or liabilities, as well as any relevant equitable considerations. The amounts paid
or payable by a party in respect of losses, claims, damages and liabilities referred to above shall be deemed to include any legal or
other fees and expenses incurred in defending any litigation, proceeding or other action or claim. Notwithstanding the provisions hereof,
the Placement Agent&rsquo;s share of the liability hereunder shall not be in excess of the amount of fees actually received, or to be
received, by the Placement Agent under the Agreement (excluding any amounts received as reimbursement of expenses incurred by the Placement
Agent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;These
Indemnification Provisions shall remain in full force and effect whether or not the transaction contemplated by the Agreement is completed
and shall survive the termination of the Agreement, and shall be in addition to any liability that the Company might otherwise have to
any indemnified party under the Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">9</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ea022620001ex4-1_180life.htm
<DESCRIPTION>COMMON STOCK PURCHASE WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">NEITHER THIS SECURITY NOR THE
SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>180
Life Sciences Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt">Warrant Shares: [_______]</TD>
    <TD STYLE="text-align: right; width: 40%; font-size: 10pt">Initial Exercise Date: December 30, 2024</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on July 1, 2030 (the
&ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from 180 Life Sciences Corp., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), up to [______] shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated December 27, 2024, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified
in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise
procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading Day
of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$2.28</B>, subject to adjustment hereunder (the
&ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part,
at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares
equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">as applicable: (i) the VWAP on the Trading Day immediately preceding
the date of the applicable Notice of Exercise if such Notice of Exercise is (1) delivered pursuant to Section 2(a) hereof on a day that
is not a Trading Day or (2) delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the
highest Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
within two (2) hours of the time of the Holder&rsquo;s delivery of the Notice of Exercise pursuant to Section 2(a) hereof if such Notice
of Exercise is delivered during &ldquo;regular trading hours,&rdquo; or with two (2) hours after the close of &ldquo;regular trading
hours,&rdquo; on a Trading Day or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after two (2) hours following
the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(X)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The
Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if the OTCQB Venture Market (&ldquo;OTCQB&rdquo;) or the OTCQX Best
Market (&ldquo;OTCQX&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and
if prices for the Common Stock are then reported on the Pink Open Market (&ldquo;Pink Market&rdquo;) operated by the OTC Markets, Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-indent: 0in; text-align: justify">d)
<U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant
to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s
share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to
such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading
Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement
Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of
(i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice
of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant
Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading
Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such
Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a
transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein,
&ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises
of the Warrant that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number
of outstanding shares of Common Stock that was provided by the Company. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and
the Company shall have no obligation to verify or confirm the accuracy of such determination. For purposes of this Section 2(e), in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in
(A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares
of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally
and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares
of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant,
by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was
reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [9.99/4.99%] of the number of shares of Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice
to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such
notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. If the
Warrant is unexercisable solely as a result of the Holder&rsquo;s Beneficial Ownership Limitation, no alternate consideration is owing
to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than
50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power
of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations
of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead
to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities,
jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor
Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with
the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company
herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of
(i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental
Transaction occurs prior to the Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to
such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice
or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such
notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the
Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the
effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights)
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this
Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of
this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results
in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder
in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="text-transform: uppercase"><B>180
                                            Life Sciences Corp.</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 4%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 36%">Name:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;180
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; in
lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744;  if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(4) <U>Accredited Investor</U>.
The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Name:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font-size: 10pt"><U></U>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">Address:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font-size: 10pt"><U></U>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print) </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Phone Number: </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Email Address:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">Dated: _______________ __, ______</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Signature:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 20%">Holder&rsquo;s Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font-size: 10pt; width: 30%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ea022620001ex5-1_180life.htm
<DESCRIPTION>OPINION OF THE LOEV LAW FIRM, PC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">December 30, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">180 Life Sciences Corp.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3000 El Camino Real, Bldg. 4, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Palo Alto, California 94306</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Registration Statement on Form S-3 (333-265416)</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to
180 Life Sciences Corp., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the above-referenced registration
statement (the &ldquo;<U>Registration Statement</U>&rdquo;), the base prospectus dated June 24, 2022 (the &ldquo;<U>Base Prospectus</U>&rdquo;)
and the prospectus supplement dated December 27, 2024 (the &ldquo;<U>Prospectus Supplement</U>&rdquo; and together with the Base Prospectus,
the &ldquo;<U>Prospectus</U>&rdquo;), relating to the offering by the Company of 1,200,000 shares (the &ldquo;<U>Shares</U>&rdquo;) of
the Company&rsquo;s common stock, par value $0.0001 per share (&ldquo;<U>Common Stock</U>&rdquo;). The Shares are being offered and sold
pursuant to that certain Securities Purchase Agreement, dated as of December 27, 2024 (the &ldquo;<U>Purchase Agreement</U>&rdquo;), by
and among the Company and the purchasers identified on the signature pages thereto and in the manner contemplated by the Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this opinion,
we have examined such documents and reviewed such questions of law as we have considered necessary and appropriate for the purposes of
our opinion set forth below. In rendering our opinion, we have assumed the authenticity of all documents submitted to us as originals,
the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies. We have also assumed
the legal capacity for all purposes relevant hereto of all natural persons and, with respect to all parties to agreements or instruments
relevant hereto other than the Company, that such parties had the requisite power and authority (corporate or otherwise) to execute, deliver
and perform such agreements or instruments, that such agreements or instruments have been duly authorized by all requisite action (corporate
or otherwise), executed and delivered by such parties and that such agreements or instruments are the valid, binding and enforceable obligations
of such parties. As to questions of fact material to our opinions, we have relied upon certificates of officers of the Company and of
public officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With your permission, we have
made and relied upon the following assumptions, without any independent investigation or inquiry by us, and our opinion expressed below
is subject to, and limited and qualified by the effect of, such assumptions: (1)&nbsp;all corporate records furnished to us by the Company
are accurate and complete; (2)&nbsp;the Registration Statement to be filed by the Company with the Commission will be identical to the
form of the document that we have reviewed; (3)&nbsp;all statements as to factual matters that are contained in the Registration Statement
(including the exhibits to the Registration Statement)&nbsp;are accurate and complete; and (4)&nbsp;in connection with each issuance of
any Shares, the Company will duly execute and deliver a stock certificate evidencing the Shares or, with respect to any Shares issued
on an uncertificated basis, the Company will comply with applicable laws regarding the documentation of uncertificated securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also assumed (i)&nbsp;the
legal capacity of all natural persons, (ii)&nbsp;the genuineness of all signatures, (iii)&nbsp;the authority of all persons signing all
documents submitted to us on behalf of the parties to such documents, (iv)&nbsp;the authenticity of all documents submitted to us as originals,
(v)&nbsp;the conformity to authentic original documents of all documents submitted to us as copies, and (vi)&nbsp;that all information
contained in all documents reviewed by us is true, correct and complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon and subject to
the foregoing, we are of the opinion that the Shares have been duly authorized and, when issued and paid for as described in the Prospectus
Supplement and pursuant to the terms of the Purchase Agreement, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is expressly
limited in scope to the Shares enumerated herein which are to be expressly covered by the referenced Registration Statement.&nbsp;Without
limiting the generality of the foregoing, we neither express nor imply any opinion regarding the contents of the Registration Statement,
other than as expressly stated above with respect to the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We express no opinion as to
the laws of any state or jurisdiction other than the State of Delaware and the federal laws of the United States of America. No opinion
is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign
jurisdiction. We have made such examination of Delaware law as we have deemed relevant for purposes of this opinion. We express no opinion
as to any county, municipal, city, town or village ordinance, rule, regulation or administrative decision. The references and limitations
to the laws of the &ldquo;<U>State of Delaware</U>&rdquo; include all applicable Delaware statutory provisions of law and reported judicial
decisions interpreting these laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion (i)&nbsp;is rendered
in connection with the filing of the Prospectus Supplement, (ii)&nbsp;is rendered as of the date hereof, and we undertake no, and hereby
disclaim any kind of, obligation to advise you of any change or any new developments that might affect any matters or opinions set forth
herein, and (iii)&nbsp;is limited to the matters stated herein and no opinions may be inferred or implied beyond the matters expressly
stated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the filing
of this opinion with the Securities and Exchange Commission as an exhibit to the Registration Statement and further consent to statements
made therein regarding our firm and use of our name under the heading &ldquo;<U>Legal Matters</U>&rdquo; in the prospectus constituting
a part of such Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose
consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ The Loev Law Firm, PC&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ea022620001ex10-1_180life.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><B>SECURITIES
PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of December 27, 2024, between 180 Life Sciences Corp., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to (i) an effective registration statement under the Securities Act (as defined
below) as to the Shares and (ii) an exemption from the registration requirements of Section 5 of the Securities Act contained in Section
4(a)(2) thereof and/or Regulation D thereunder as to the Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser,
severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1<SUP>st</SUP>)
Trading Day following the date hereof (or second 2<SUP>nd</SUP> Trading Day if this Agreement is executed after 4:00 p.m. (New York City
Time) but prior to 11:59 p.m. (New York City Time) following the date hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means The Loev Law Firm, PC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof,
unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options or other equity awards to employees, officers, directors
or consultants of the Company pursuant to any equity incentive plan duly adopted for such purpose, by a majority of the non-employee members
of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose or for services
rendered to the Company for investor relations services, provided that such securities are issued as &ldquo;restricted securities&rdquo;
(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith during the prohibition period and that such issuances shall not exceed 200,000 shares of Common Stock (including shares issuable
upon the exercise of any options), (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or
other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this
Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities
or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or
combinations) or to extend the term of such securities, (c) securities issued pursuant to acquisitions or strategic transactions or issued
in connection with any joint venture, commercial or collaborative relationship, or the acquisition or license by the Company of the securities,
business, property or other assets of another person, in each case approved by a majority of the disinterested directors of the Company,
provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights
that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a)
herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through
its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company, as determined
by the Board of Directors in good faith, and shall provide to the Company additional benefits in addition to the investment of funds,
but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity
whose primary business is investing in securities, (d) Securities issued in consideration for debt conversions and settlements, provided
that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that
require or permit the filing of any registration statement in connection therewith during the prohibition period or (e) the securities
sold pursuant to the registration statement on Form S-1 (File No. 333-283265).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and officers
and holders of the Company&rsquo;s Series B Preferred Stock, in the form of <U>Exhibit B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Participation
Maximum</U>&rdquo; shall have the meaning ascribed to such term in Section 4.9(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals $2.41, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Product</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means Maxim Group LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission
and delivered by the Company to each Purchaser at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No. 333-265416 which registers the sale of the Shares
to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in
United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, the Pink Market, OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Continental Stock Transfer &amp; Trust Company, the current transfer agent of the Company, and any successor transfer
agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if the OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;) or the
OTCQX Best Market (&ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such
date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading
on OTCQB or OTCQX and if prices for the Common Stock are then reported in the Pink Open Market (&ldquo;<U>Pink Market</U>&rdquo;) operated
by OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price
per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and
reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof,
which Warrants shall be exercisable immediately and have a term of exercise equal to 5.5 years from the date of issuance, in the form
of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1 <U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally
and not jointly, agree to purchase, up to an aggregate of $2,892,000 of Shares and Warrants. Each Purchaser&rsquo;s Subscription Amount
as set forth on the signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo;
settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares and a Warrant as determined
pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the
Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by
electronic transfer of the Closing documentation. Notwithstanding anything herein to the contrary, if at any time on or after the time
of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing
(the &ldquo;<U>Pre-Settlement Period</U>&rdquo;), such Purchaser sells to any Person all, or any portion, of the Shares to be issued hereunder
to such Purchaser at the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Purchaser shall, automatically hereunder
(without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such Pre-Settlement
Shares at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to
the Company&rsquo;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that the Company hereby
acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during
the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares
of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any. Unless otherwise
directed by the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;)
(i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by
the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement
Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement
Agent (or its clearing firm) by wire transfer to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2 <U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) On
or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i) this
Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) a
legal opinion of Company Counsel, substantially in the form acceptable to the Placement Agent and the Purchasers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii) subject
to the last sentence of Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company
letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv) Subject
to the last sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver
on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal
to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v) a
Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of such Purchaser&rsquo;s
Shares, with an exercise price equal to $2.28, subject to adjustment therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi) on
the date hereof, the duly executed Lock-Up Agreements; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii) the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i) this
Agreement duly executed by such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) such
Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company
or its designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3 <U>Closing
Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on the
Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case
they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in all
respects) as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii) the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein in which case they shall be accurate in all respects or, to the extent representations or warranties are qualified
by materiality or Material Adverse Effect, in all respects) as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii) the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv) there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v) from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude
in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser,
makes it impracticable or inadvisable to purchase the Securities at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1 <U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part
hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section
of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary, free and clear of any Liens, except as set for in the SEC Reports
and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries,
taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis
its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation
by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or
therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party
has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof,
will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)
as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it
is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do
not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles of
incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with
notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets
of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property
or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in
a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not
have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection
with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant
to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s) to each applicable
Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, (iv) the
filing of Form D with the Commission and such filings as are required to be made under applicable state securities laws (collectively,
the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.
The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free
and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares
of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement in
conformity with the requirements of the Securities Act, which became effective on&nbsp;June 24, 2022 (the &ldquo;<U>Effective Date</U>&rdquo;),
including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration
Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement
or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been
instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations
of the Commission, shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any
amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments
thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement
thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading. The Company was at the time of the
filing of the Registration Statement eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities Act and it
meets the transaction requirements with respect to the aggregate market value of securities being sold pursuant to this offering and during
the twelve (12) months prior to this offering, as set forth in General Instruction I.B.6 of Form S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) <U>Capitalization</U>.
The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which <U>Schedule 3.1(g)</U> shall
also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof.
The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant
to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees
pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents
outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal,
preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.
Except as a result of the purchase and sale of the Securities and as set forth on <U>Schedule 3.1(g)</U>, there are no outstanding options,
warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations
convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common
Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The
issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities
to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any
provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities
by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any
redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any
Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation
rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock
of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance in all material respects
with all federal and state securities laws where applicable, and none of such outstanding shares was issued in violation of any preemptive
rights or similar rights to subscribe for or purchase securities. Except for the Required Approvals, no further approval or authorization
of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a
party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) <U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two
years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus
Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates,
the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and
none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to
be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting
requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements
have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the
periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and
except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that has had or
that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no
event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with
respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed
made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) <U>Litigation</U>.
Except as set forth &nbsp;in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending
or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;) that would reasonably be expected to result in a Material Adverse Effect. None of the Actions
set forth in the SEC Reports<U>:</U> (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction
Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material
Adverse Effect. Except as set forth &nbsp;in the SEC Reports, neither the Company nor any Subsidiary, nor any director or officer thereof,
is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim
of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation
by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any
stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the
Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k) <U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement
or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued
employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any
of the foregoing matters that would reasonably be expected to results in a Material Adverse Effect. The Company and its Subsidiaries are
in compliance with all applicable U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices,
terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l) <U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority
or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality
and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m) <U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to
pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or
subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the
environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or
handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder
(&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have received all permits licenses or other approvals required of them under
applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of
any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected
to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n) <U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o) <U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each
case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal,
state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither
delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by
them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance, except where the failure
to so comply would not reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p) <U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement
except for such expirations, terminations or abandonments which would not reasonably be expected to have a Material Adverse Effect. Neither
the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports,
a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of
any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company,
all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and
value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q) <U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited
to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary
has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r) <U>Transactions
With Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of the Company or
any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any
transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s) <U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley
Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the
Commission thereunder that are effective as of the date hereof and as of the Closing Date. Except as set forth on Schedule 3.1(s), the
Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions
are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted
only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the
Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company
and the Subsidiaries and designed such disclosure controls and procedures to provide reasonable assurance that information required to
be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported,
within the time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated the
effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the
most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented
in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of
the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been
no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries
that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company
and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t) <U>Certain
Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions are or will
be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section
that may be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u) <U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company
shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration under the
Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v) <U>Registration
Rights</U>. Except as set forth in the SEC Reports, no Person has any right to cause the Company to effect the registration under the
Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w) <U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company
has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.
Except as set forth on <U>Schedule 3.1(w)</U>, the Company has not, in the 12 months preceding the date hereof, received notice from any
Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the
listing or maintenance requirements of such Trading Market. Except as set forth on Schedule 3.1(w), the Company is, and has no reason
to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation
and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in
connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x) <U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s issuance of
the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y) <U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus Supplement.
The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities
of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries,
their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and
correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated
by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser
makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically
set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z) <U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales
of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be
integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of the Warrants
or Warrant Shares under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any
of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa) <U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry
on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital
availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it
to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts
on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its
ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its
debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or
liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. <U>Schedule
3.1(aa)</U> sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or
for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means
(x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the
ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of
others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto),
except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course
of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in
accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb) <U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is
subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to
be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment
of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no
unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company
or of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc) <U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or
other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or
campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by
any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material
respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd) <U>Accountants</U>.
The Company&rsquo;s accounting firm is set forth on <U>Schedule 3.1(dd)</U> of the Disclosure Schedules. To the knowledge and belief
of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall
express its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year
ending December 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee) <U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting
solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any
advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and
the transactions contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further
represents to each Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has
been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff) <U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U><FONT STYLE="text-decoration: none">. Anything in this Agreement or elsewhere herein
to the contrary notwithstanding (except for Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged by the Company that:
(i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling,
long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to
hold the Securities for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including,
without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement
transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties
in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo;
position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s
length counter-party in any &ldquo;derivative&rdquo; transaction. </FONT>The Company further understands and acknowledges that (y) one
or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including,
without limitation, during the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined,
and (z) such hedging activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at and
after the time that the hedging activities are being conducted.&nbsp; The Company acknowledges that such aforementioned hedging activities
do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg) <U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement
of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh) <U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance with
the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common
Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&rsquo;s
stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice
to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public
announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) <U>Cybersecurity</U>.
Except as would not, individually or in the aggregate, have a Material Adverse Effect (i)(x) there has been no security breach or other
compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s information technology and computer systems, networks,
hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained
by or on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries
have not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security
breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable
laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority,
internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such
IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate,
have a Material Adverse Effect; (iii)&nbsp;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards
to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with
commercially reasonable industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj) <U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee
or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk) <U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll) <U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956,
as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to
regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm) <U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or
any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn) <U>Compliance
with Data Privacy Laws</U>. (i)&nbsp;The Company and the Subsidiaries are, and at all times during the last three (3) years were, in compliance
with all applicable state, federal and foreign data privacy and security laws and regulations, including, without limitation, the European
Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy Laws</U>&rdquo;);
(ii)&nbsp;the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance
with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis
of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii)&nbsp;the Company provides accurate notice of its applicable
Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws; and (iv)&nbsp;applicable
Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating to its subject matter,
and do not contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by Privacy Laws.&nbsp;&ldquo;<U>Personal
Data</U>&rdquo; means (i)&nbsp;a natural person&rsquo;s name, street address, telephone number, email address, photograph, social security
number, bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &ldquo;personally identifying
information&rdquo; under the Federal Trade Commission Act, as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR; and (iv)&nbsp;any
other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis
of any identifiable data related to an identified person&rsquo;s health or sexual orientation. (i)&nbsp;None of such disclosures made
or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii)&nbsp;the
execution, delivery and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies.&nbsp; Neither
the Company nor the Subsidiaries (i)&nbsp;to the knowledge of the Company, has received written notice of any actual or potential liability
of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy Laws;
(ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant
to any regulatory request or demand pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement by or with
any court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(oo) <U>Private
Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no registration
under the Securities Act is required for the offer and sale of the Warrants or the Warrant Shares by the Company to the Purchasers as
contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(pp) <U>No General
Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Warrant or Warrant
Shares by any form of general solicitation or general advertising. The Company has offered the Warrants and Warrant Shares for sale only
to the Purchasers and certain other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(qq) <U>No Disqualification
Events</U>. With respect to the Warrant and Warrant Shares to be offered and sold hereunder in reliance on Rule 506 under the Securities
Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company
participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding voting equity securities,
calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with
the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo;) is subject to any of the &ldquo;Bad
Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;),
except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether
any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure
obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(rr) <U>Other
Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that
has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ss) <U>Notice
of Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become
a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2 <U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in">(a) <U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in">(b) <U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.
Such Purchaser understands that the Warrants and the Warrant Shares are &ldquo;restricted securities&rdquo; and have not been registered
under the Securities Act or any applicable state securities law and is acquiring such Securities as principal for his, her or its own
account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities
Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute
or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation
and warranty not limiting such Purchaser&rsquo;s right to sell such Securities pursuant to a registration statement or otherwise in compliance
with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in">(c) <U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Warrants, it will be an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8),
(a)(9), (a)(12) or (a)(13) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in">(d) <U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in">(e) <U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment.&nbsp; Such Purchaser acknowledges and agrees that neither the
Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the
Securities nor is such information or advice necessary or desired.&nbsp; Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it.&nbsp; In connection with the issuance
of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary
to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in">(f) <U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material pricing
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in">(g) <U>Independent
Advice</U>. Each Purchaser understands that nothing in this Agreement or any other materials presented by or on behalf of the Company
to the Purchaser in connection with the purchase of the Securities constitutes legal, tax or investment advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in">(h)
<U>General Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or
presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in">The Company acknowledges and
agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on
the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or
similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.1 <U>Removal
of Legends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) The
Warrants and Warrant Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer
of Warrants or Warrant Shares other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate
of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide
to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which
opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred
Warrant under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)
The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Warrants or Warrant Shares
in the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES
INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF
ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED
INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The Company acknowledges
and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant
a security interest in some or all of the Warrants or Warrant Shares to a financial institution that is an &ldquo;accredited investor&rdquo;
as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer pledged
or secured Warrants or Warrant Shares to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of
the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith.
Further, no notice shall be required of such pledge. At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver
such reasonable documentation as a pledgee or secured party of Warrants and Warrant Shares may reasonably request in connection with a
pledge or transfer of the Warrants or Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Certificates
evidencing the Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while a registration
statement covering the resale of such security is effective under the Securities Act, or (ii) following any sale of such Warrant Shares
pursuant to Rule 144 (assuming cashless exercise of the Warrants), or (iii) if such Warrant Shares are eligible for sale under Rule 144
(assuming cashless exercise of the Warrants), or (iv) if such legend is not required under applicable requirements of the Securities Act
(including judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to
issue a legal opinion to the Transfer Agent or the Purchaser promptly if required by the Transfer Agent to effect the removal of the legend
hereunder, or if requested by a Purchaser, respectively. If all or any portion of a Warrant is exercised at a time when there is an effective
registration statement to cover the resale of the Warrant Shares, or if such Warrant Shares may be sold under Rule 144 (assuming cashless
exercise of the Warrants) or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the staff of the Commission) then such Warrant Shares shall be issued free of all legends.
The Company agrees that following such time as such legend is no longer required under this Section 4.1(c), the Company will, no later
than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Warrant Shares, as applicable,
issued with a restrictive legend (such date, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser
a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its
records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Warrant Shares
subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s
prime broker with the Depository Trust Company System as directed by such Purchaser. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of a certificate representing Warrant Shares issued with a restrictive legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) In
addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares (based on the VWAP of the Common Stock on the date such Securities are
submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day (increasing
to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date
until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered)
to a Purchaser by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such Purchaser that
is free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction
or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares
of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock,
that such Purchaser anticipated receiving from the Company without any restrictive legend, then an amount equal to the excess of such
Purchaser&rsquo;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common
Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<FONT STYLE="font-weight: normal"><U>Buy-In
Price</U></FONT>&rdquo;) over the product of (A) such number of Warrant Shares that the Company was required to deliver to such Purchaser
by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing
on the date of the delivery by such Purchaser to the Company of the applicable Warrant Shares (as the case may be) and ending on the date
of such delivery and payment under this Section 4.1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) The
Shares shall be issued free of legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2 <U>Furnishing
of Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) Until
the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to timely file
(or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company
after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) At
any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the Warrant
Shares (assuming cashless exercise) may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise
without restriction or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information
requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future, and the
Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &ldquo;<U>Public Information Failure</U>&rdquo;) then, in addition
to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not
as a penalty, by reason of any such delay in or reduction of its ability to sell the Warrant Shares, an amount in cash equal to two percent
(2.0%) of the aggregate Exercise Price of such Purchaser&rsquo;s Warrants on the day of a Public Information Failure and on every thirtieth
(30<SUP>th</SUP>) day (pro rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public
Information Failure is cured and (b) such time that such public information is no longer required&nbsp; for the Purchasers to transfer
the Warrant Shares pursuant to Rule 144.&nbsp; The payments to which a Purchaser shall be entitled pursuant to this Section 4.2(b) are
referred to herein as &ldquo;<U>Public Information Failure Payments</U>.&rdquo;&nbsp; Public Information Failure Payments shall be paid
on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred and (ii) the
third (3<SUP>rd</SUP>) Business Day after the event or failure giving rise to the Public Information Failure Payments is cured.&nbsp;
In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments
shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit such Purchaser&rsquo;s
right to pursue actual damages for the Public Information Failure, and such Purchaser shall have the right to pursue all remedies available
to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3 <U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section
2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration
under the Securities Act of the sale of the Warrants or Warrant Shares or that would be integrated with the offer or sale of the Securities
for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of
such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4 <U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the
transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto,
with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents
to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the
Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without
limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective
upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under
any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any of their Affiliates
on the other hand, shall terminate and be no further force or effect. The Company understands and confirms that each Purchaser shall be
relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult
with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor
any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company,
with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release
of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case
the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with
the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required
by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such
disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice
of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5 <U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6 <U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its
behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes,
material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information
and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser
shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any
of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall not
have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates
or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of their respective
officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade on the basis of,
such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice
provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any
Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant to a Current
Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions
in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7 <U>Use
of Proceeds</U>. Except as set forth on <U>Schedule 4.7</U> attached hereto, the Company shall use the net proceeds from the sale of the
Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s
debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption
of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC
regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8 <U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners
or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such
title or any other title) of such controlling persons (each, a &ldquo;Purchaser Party&rdquo;) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and
reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating
to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other
Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates,
by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated
by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations,
warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such
stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which
is finally judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall be brought against any
Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the
Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the
defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i)
the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period
of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company
shall be responsible for the reasonable and documented fees and expenses of no more than one such separate counsel. The Company will not
be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s
prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss,
claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, other Transaction Documents.
The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or are incurred; provided, however, that if it is subsequently determined by a final, non-appealable
judgment of a court of competent jurisdiction that a Purchaser was not entitled to receive such periodic payments, such Purchaser shall
promptly (but in no event later than five (5) Business Days) return such payments to the Company. The indemnity agreements contained herein
shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities
the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9 <U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved, free of preemptive rights, a sufficient number of shares of Common
Stock for the purpose of enabling the Company to issue Shares and Warrant Shares pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10 <U>Listing
of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading
Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares
and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market.
The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in
such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and
Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably
necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s
reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility
of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including,
without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection
with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11 <U>Participation
in Future Financing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) From
the date hereof until the earlier of (i) twelve (12) months from the Closing Date and (ii) the Company consummates equity financings for
aggregate proceeds equal to $7,000,000, upon any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
for cash consideration, Indebtedness or a combination of units thereof (a &ldquo;<U>Subsequent Financing</U>&rdquo;), each Purchaser shall
have the right to participate in up to an amount of the Subsequent Financing equal to an aggregate of 30% of the Subsequent Financing
(the &ldquo;<U>Participation Maximum</U>&rdquo;) on the same terms, conditions and price provided for in the Subsequent Financing.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) Between
the time period of 4:00 pm (New York City time) and 6:00 pm (New York City time) on the Trading Day immediately prior to the Trading Day
of the expected announcement of the Subsequent Financing (or, if the Trading Day of the expected announcement of the Subsequent Financing
is the first Trading Day following a holiday or a weekend (including a holiday weekend), between the time period of 4:00 pm (New York
City time) on the Trading Day immediately prior to such holiday or weekend and 2:00 pm (New York City time) on the day immediately prior
to the Trading Day of the expected announcement of the Subsequent Financing), the Company shall deliver to each Purchaser a written notice
of the Company&rsquo;s intention to effect a Subsequent Financing (a &ldquo;<U>Subsequent Financing Notice</U>&rdquo;), which notice shall
describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds intended to be raised thereunder
and the Person or Persons through or with whom such Subsequent Financing is proposed to be effected and shall include a term sheet and
transaction documents relating thereto as an attachment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Any
Purchaser desiring to participate in such Subsequent Financing must provide written notice to the Company by 11:59 pm (New York City time)
on the date on which the Subsequent Financing Notice is delivered to such Purchaser (the &ldquo;<U>Notice Termination Time</U>&rdquo;)
that such Purchaser is willing to participate in the Subsequent Financing, the amount of such Purchaser&rsquo;s participation, and representing
and warranting that such Purchaser has such funds ready, willing, and available for investment on the terms set forth in the Subsequent
Financing Notice. If the Company receives no such notice from a Purchaser as of such Notice Termination Time, such Purchaser shall be
deemed to have notified the Company that it does not elect to participate in such Subsequent Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) If,
by the Notice Termination Time, notifications by the Purchasers of their willingness to participate in the Subsequent Financing (or to
cause their designees to participate) is, in the aggregate, less than the total amount of the Subsequent Financing, then the Company may
effect the remaining portion of such Subsequent Financing on the terms and with the Persons set forth in the Subsequent Financing Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) If,
by the Notice Termination Time, the Company receives responses to a Subsequent Financing Notice from Purchasers seeking to purchase more
than the aggregate amount of the Participation Maximum, each such Purchaser shall have the right to purchase its Pro Rata Portion (as
defined below) of the Participation Maximum.&nbsp; &ldquo;<U>Pro Rata Portion</U>&rdquo; means the ratio of (x) the Subscription Amount
of Shares purchased on the Closing Date by a Purchaser participating under this Section 4.11 and (y) the sum of the aggregate Subscription
Amounts of Shares purchased on the Closing Date by all Purchasers participating under this Section 4.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) The
Company must provide the Purchasers with a second Subsequent Financing Notice, and the Purchasers will again have the right of participation
set forth above in this Section 4.11, if the definitive agreement related to the initial Subsequent Financing Notice is not entered into
for any reason on the terms set forth in such Subsequent Financing Notice within two (2) Trading Days after the date of delivery of the
initial Subsequent Financing Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">(g) </FONT>The
Company and each Purchaser agree that, if any Purchaser elects to participate in the Subsequent Financing, the transaction documents related
to the Subsequent Financing shall not include any term or provision that, directly or indirectly, will, or is intended to, exclude one
or more of the Purchasers from participating in a Subsequent Financing, including, but not limited to, provisions whereby such Purchaser
shall be required to agree to any restrictions on trading as to any the securities of the Company or be required to consent to any amendment
to or termination of, or grant any waiver, release or the like under or in connection with, this Agreement, without the prior written
consent of such Purchaser. In addition, the Company and each Purchaser agree that, in connection with a Subsequent Financing, the transaction
documents related to the Subsequent Financing shall include a requirement for the Company to issue a widely disseminated press release
by 9:30 am (New York City time) on the Trading Day of execution of the transaction documents in such Subsequent Financing (or, if the
date of execution is not a Trading Day, on the immediately following Trading Day) that discloses the material terms of the transactions
contemplated by the transaction documents in such Subsequent Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) Notwithstanding
anything to the contrary in this Section 4.11 and unless otherwise agreed to by such Purchaser, the Company shall either confirm in writing
to such Purchaser that the transaction with respect to the Subsequent Financing has been abandoned or shall publicly disclose its intention
to issue the securities in the Subsequent Financing, in either case in such a manner such that such Purchaser will not be in possession
of any material, non-public information, by 9:30 am (New York City time) on the second (2nd) Trading Day following date of delivery of
the Subsequent Financing Notice. If by 9:30 am (New York City time) on such second (2nd) Trading Day, no public disclosure regarding a
transaction with respect to the Subsequent Financing has been made, and no notice regarding the abandonment of such transaction has been
received by such Purchaser, such transaction shall be deemed to have been abandoned and such Purchaser shall not be deemed to be in possession
of any material, non-public information with respect to the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) Notwithstanding
anything to the contrary pursuant to a Purchaser&rsquo;s (and its Affiliates) rights to its Participation Maximum pursuant to this Section
4.11, if the number of shares of Common Stock issuable to a Purchaser (and its Affiliates) pursuant to any proposed Subsequent Financing,
when aggregated with all other shares of Common Stock beneficially owned by such Purchaser (and its Affiliates) at such time of such Subsequent
Financing, would result in such Purchaser (and its Affiliates) beneficially owning (as determined in accordance with Section 13(d) of
the Exchange Act) in excess of 4.99% (or 9.99% at the election of the Purchaser) of the then issued and outstanding Common Stock outstanding
at the closing of the Subsequent Financing (the &ldquo;<U>ROP Beneficial Ownership Maximum</U>&rdquo;), then in lieu of receiving shares
of Common Stock in a Subsequent Financing that would result in such Purchaser (and its Affiliates) exceeding the ROP Beneficial Ownership
Maximum, such Purchaser (and its Affiliates) shall receive Common Stock Equivalents (such as pre-funded Common Stock purchase warrants)
with a customary beneficial ownership blocker, in order for such Purchaser (and its Affiliates) to maintain a beneficial ownership at
or below the ROP Beneficial Ownership Maximum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) Notwithstanding
the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12 <U>Subsequent
Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) From
the date hereof until thirty (30) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any
agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file
any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant to
Section 4.18 herein or filing a registration statement on Form S-8 in connection with any employee benefit plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) From
the date hereof until thirty (30) days after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement
to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units
thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company
(i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to
receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based
upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such
debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after
the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related
to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities
at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether
such agreement is subsequently canceled, provided, however, securities sold pursuant to the registration statement on Form S-1 (File No.
333-283265) shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company
to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Notwithstanding
the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an
Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13 <U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is
also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers
as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition
or voting of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.14 <U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor
any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales
of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time that
the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section
4.4.&nbsp; Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated
by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser
will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules
(other than as disclosed to its legal and other representatives).&nbsp; Notwithstanding the foregoing and notwithstanding anything contained
in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty
or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions
contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no
Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable
securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to
the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade
in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates
or agent, including, without limitation, the Placement Agent, after the issuance of the initial press release as described in Section
4.4.&nbsp; Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio
managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment
decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall
only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities
covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.15 <U>Capital
Changes</U>. Until the one year anniversary of the Closing Date, the Company shall not undertake a reverse or forward stock split or reclassification
of the Common Stock without the prior written consent of the Purchasers holding a majority in interest of the Shares other than a reverse
stock split that is required, in the good faith determination of the Board of Directors, to maintain the listing of the Common Stock on
the Trading Market, which consent shall not be unreasonably withheld, conditioned or delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.16 <U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers
in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers
to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise the
Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions
and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.17 <U>Form
D; Blue Sky Filings</U>. The Company agrees to timely file a Form D with respect to the Warrant and Warrant Shares as required under Regulation
D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably
determine is necessary in order to obtain an exemption for, or to qualify the Warrant and Warrant Shares for, sale to the Purchasers at
the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States, and shall provide evidence
of such actions promptly upon request of any Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.18 <U>Registration
Statement</U>. As soon as practicable (and in any event within 30 calendar days of the date of this Agreement), the Company shall file
a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) providing for the resale by the
Purchasers of the Warrant Shares issued and issuable upon exercise of the Warrants.&nbsp; The Company shall use commercially reasonable
efforts to cause such registration statement to become effective within 91 days following the Closing Date and to keep such registration
statement effective at all times until no Purchaser owns any Warrants or Warrant Shares issuable upon exercise thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.19 <U>Lock-Up
Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend
the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to
a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific performance
of the terms of such Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1 <U>Termination</U>.&nbsp;
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated
on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such termination
will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2 <U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without
limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered
by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3 <U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4 <U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email
attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a
Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment
at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as set forth on the signature pages attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5 <U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial
Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and
adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser
relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected
Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6 <U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7 <U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other
than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or
transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by
the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8 <U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of the Company
in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit of
the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be
enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9 <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section
4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.10 <U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11 <U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12 <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13 <U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of
the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw,
in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part
without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission of an exercise of
a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice
concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration
of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance of a replacement
warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14 <U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15 <U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby
agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would
be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16 <U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser
enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part
thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required
to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without
limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration
the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such
payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17 <U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and
not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so
by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and
among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18 <U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents
is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been
paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due
and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19 <U>Saturdays, Sundays,
Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.20 <U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.21 <B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><B>180 Life sciences corp.</B></TD>
    <TD>&nbsp;</TD>
    <TD><U>Address for Notice:</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 31%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%">E-Mail:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">With a copy to (which shall not constitute notice):</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO ATNF SECURITIES PURCHASE
AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: __________________ Beneficial Ownership Blocker &#9744;
4.99% or &#9744; 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744; Notwithstanding anything contained
in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth
in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities
to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur on the
first (1<SUP>st</SUP>) Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated by this
Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any
agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be
an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or
the like or purchase price (as applicable) to such other party on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ea022620001ex99-1_180life.htm
<DESCRIPTION>PRESS RELEASE DATED DECEMBER 27, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>180 Life Sciences Corp. Announces Pricing of
$2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PALO ALTO, CA / ACCESSWIRE / December 27, 2024
/</B>&nbsp;180 Life Sciences Corp. (&ldquo;<B>180</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;) (NASDAQ:ATNF), a biotechnology company that
is currently refocusing its business on the international entertainment and iGaming sector, today announced that it has entered into a
securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct offering
priced at market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase
up to an aggregate of 1,200,000 shares of common stock. The combined effective offering price for each share of common stock and accompanying
warrants is $2.41. The warrants will have an exercise price of $2.28 per share, will be exercisable immediately, and expire on the five
and a half year anniversary from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds to the Company from the registered
direct offering and concurrent private placement are estimated to be approximately $2.9 million before deducting the placement agent&rsquo;s
fees and other offering expenses payable by the Company. The offering is expected to close on or about December 30, 2024, subject to the
satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maxim Group LLC is acting as the sole placement
agent in connection with the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock are being offered pursuant
to a shelf registration statement on Form S-3 (File No. 333-265416), which was declared effective by the U.S. Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) on June 24, 2022. The offering of shares of common stock will be made only by means of a prospectus
supplement that forms a part of such registration statement. The warrants to be issued in the concurrent private placement and the shares
issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended
(the &ldquo;Act&rdquo;), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release does not constitute an offer
to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus
supplement relating to the shares of common stock will be filed by the Company with the SEC. When available, copies of the prospectus
supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC&rsquo;s website
at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com
or telephone at (212) 895-3500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About 180 Life Sciences Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">180 Life Sciences Corp. is an innovative biotechnology
company that is focused on advancing breakthrough treatments. With recent moves into the online gaming sector, the Company is leveraging
its expertise and new strategic appointments to capitalize on the expanding opportunities in this market. The Company is dedicated to
leveraging its recently acquired proprietary Technology Gaming Platform and expertise to capture emerging trends, particularly in cryptocurrency
and blockchain technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information, please visit&nbsp;www.180lifesciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release includes &ldquo;forward-looking
statements&rdquo;, including information about management&rsquo;s view of the Company&rsquo;s future expectations, plans and prospects, within the
safe harbor provisions provided under federal securities laws, including under The Private Securities Litigation Reform Act of 1995 (the
&ldquo;Act&rdquo;). Words such as &ldquo;expect,&rdquo; &ldquo;estimate,&rdquo; &ldquo;project,&rdquo; &ldquo;budget,&rdquo; &ldquo;forecast,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo;
&ldquo;believes,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue&rdquo; and similar expressions are intended to identify
such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual
results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions
of future events. These forward-looking statements and factors that may cause such differences include, without limitation, statements
regarding the consummation of the offering, the satisfaction of customary closing conditions related to the offering and the use of proceeds
in the offering; the ability of the Company to maintain the continued listing of the Company&rsquo;s securities on The Nasdaq Stock Market;
the Company&rsquo;s ability to raise funding to support its operations and commercialize its newly acquired Gaming Technology Platform; the
Company&rsquo;s ability to commercialize its Gaming Technology Platform; the lack of experience of current management with operating a gaming
company; the ability of the Company to build out or acquire a front end for the Gaming Technology Platform, and the costs and timing associated
therewith; the ability of the Company to generate revenue from the Gaming Technology Platform, including timing and cost thereof; our
need for significant additional funding, the ability of the Company to raise funding, the terms of such funding, and dilution caused thereby;
competition in the iGaming industry; risks relating to fraud, theft or cheating; our ability to obtain and maintain licenses, and the
terms thereof; our required reliance on third party cloud service providers and providers of third-party communications infrastructure,
hardware and software; the review and evaluation of strategic transactions and their impact on shareholder value; the process by which
the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof;
our ability to commercialize our drug candidates, if proven successful for treatment in trials; risks regarding whether the administrative
processes required for the issuance of patents will be completed in a timely manner or at all; risks regarding the outcome of pharmaceutical
studies, the timing and costs thereof, and the ability to obtain sufficient participants; the timing of, outcome of, and results of, clinical
trials statements regarding the timing of marketing authorization application (MAA) submissions to the UK Medicines and Healthcare products
Regulatory Agency (MHRA) and New Drug Application submissions (NDA) to the U.S. Food and Drug Administration (FDA), our ability to obtain
approval and acceptance thereof, the willingness of the MHRA to review such MAA and the FDA to review such NDA, and our ability to address
outstanding comments and questions from the MHRA and FDA; statements about the ability of our clinical trials to demonstrate safety and
efficacy of our product candidates, and other positive results; the uncertainties associated with the clinical development and regulatory
approval of 180&rsquo;s drug candidates, including potential delays in the enrollment and completion of clinical trials, the costs thereof,
closures of such trials prior to enrolling sufficient participants in connection therewith, issues raised by the FDA, the MHRA and the
European Medicines Agency (EMA); the ability of the Company to persuade regulators that chosen endpoints do not require further validation;
timing and costs to complete required studies and trials, and timing to obtain governmental approvals; 180&rsquo;s reliance on third parties
to conduct its clinical trials, enroll patients, and manufacture its preclinical and clinical drug supplies; the ability to come to mutually
agreeable terms with such third parties and partners, and the terms of such agreements; estimates of patient populations for 180&rsquo;s planned
products; 180&rsquo;s ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and
regulations outside the United States; current negative operating cash flows and a need for additional funding to finance our operating
plans; the terms of any further financing, which may be highly dilutive and may include onerous terms, changes in interest rates which
may make borrowing more expensive and increased inflation which may negatively affect costs, expenses and returns; statements relating
to expectations regarding future agreements relating to the supply of materials and license and commercialization of products; competition,
including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws
and regulations; expectations with respect to future performance, growth and anticipated acquisitions; expectations regarding the capitalization,
resources and ownership structure of the Company; the ability of the Company to execute its plans to develop and market products and the
timing and costs of these programs; estimates of the size of the markets for the Company&rsquo;s planned products; the outcome of current litigation
involving the Company; potential future litigation involving the Company or the validity or enforceability of the intellectual property
of the Company or lawsuits alleging that we have violated the intellectual property of others; global economic conditions; geopolitical
events and regulatory changes; and the effect of changing interest rates and inflation, economic downturns and recessions, declines in
economic activity or global conflicts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These risk factors and others are included from
time to time in documents the Company files with the Securities and Exchange Commission, including, but not limited to, its Form 10-Ks,
Form 10-Qs and Form 8-Ks, and including the Annual Report on Form 10-K for the year ended December 31, 2023, and Quarterly Report on Form
10-Q for the quarter ended September 30, 2024, and future SEC filings. These reports and filings are available at www.sec.gov and are
available for download, free of charge, soon after such reports are filed with or furnished to the SEC, on the &ldquo;Investors&rdquo;,
&ldquo;SEC Filings&rdquo;, &ldquo;All SEC Filings&rdquo; page of our website at www.180lifesciences.com. All subsequent written and oral forward-looking
statements concerning the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements
above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, including
the forward-looking statements included in this press release, which are made only as of the date hereof. The Company cannot guarantee
future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking
statements. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any
forward-looking statement to reflect any change in its expectations or any change in events, conditions, or circumstances on which any
such statement is based, except as otherwise provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:</B><BR>
<BR>
Blair Jordan<BR>
Interim Chief Executive Officer<BR>
Email address:&nbsp;bjordan@180lifesciences.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !\ B\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^Z;XJ?$+Q
M+\.],TO4/#7P:^)GQGN+^_>SN='^&5U\,K74M(@6!IAJ6I-\3OB+\.-->RD=
M1;(NFZC?WWGNI>S6#=,OB7_#3?Q5_P"C$_VL?_!M^R9_]%)7U_10!\@?\--_
M%7_HQ/\ :Q_\&W[)G_T4E'_#3?Q5_P"C$_VL?_!M^R9_]%)7U_10!\@?\--_
M%7_HQ/\ :Q_\&W[)G_T4E'_#3?Q5_P"C$_VL?_!M^R9_]%)7U_10!\@?\--_
M%7_HQ/\ :Q_\&W[)G_T4E'_#3?Q5_P"C$_VL?_!M^R9_]%)7U_10!\@?\--_
M%7_HQ/\ :Q_\&W[)G_T4E'_#3?Q5_P"C$_VL?_!M^R9_]%)7U_10!\@?\--_
M%7_HQ/\ :Q_\&W[)G_T4E'_#3?Q5_P"C$_VL?_!M^R9_]%)7U_10!\@?\--_
M%7_HQ/\ :Q_\&W[)G_T4E'_#3?Q5_P"C$_VL?_!M^R9_]%)7U_10!\@?\--_
M%7_HQ/\ :Q_\&W[)G_T4E'_#3?Q5_P"C$_VL?_!M^R9_]%)7U_10!\@?\--_
M%7_HQ/\ :Q_\&W[)G_T4E'_#3?Q5_P"C$_VL?_!M^R9_]%)7U_10!\@?\--_
M%7_HQ/\ :Q_\&W[)G_T4E'_#3?Q5_P"C$_VL?_!M^R9_]%)7U_10!\@?\--_
M%7_HQ/\ :Q_\&W[)G_T4E'_#3?Q5_P"C$_VL?_!M^R9_]%)7UK<7UE:)/+=7
M=M;16L,ES<RW%Q##';6\,;333SO(ZK##%"CRR2R%8TC5G9@H)KR'X??M'? #
MXM:UKOASX6_&GX7_ !'UWPQ>+I_B/2_ WCCPYXJO-#O75VCMM4BT/4+TV4L@
MCE\M9]A<Q2A<F-PH!Y1_PTW\5?\ HQ/]K'_P;?LF?_124?\ #3?Q5_Z,3_:Q
M_P#!M^R9_P#125]?T4 ?('_#3?Q5_P"C$_VL?_!M^R9_]%)1_P --_%7_HQ/
M]K'_ ,&W[)G_ -%)7U_10!\@?\--_%7_ *,3_:Q_\&W[)G_T4E'_  TW\5?^
MC$_VL?\ P;?LF?\ T4E?7]% 'R!_PTW\5?\ HQ/]K'_P;?LF?_124?\ #3?Q
M5_Z,3_:Q_P#!M^R9_P#125]?T4 ?('_#3?Q5_P"C$_VL?_!M^R9_]%)1_P -
M-_%7_HQ/]K'_ ,&W[)G_ -%)7U_10!\@?\--_%7_ *,3_:Q_\&W[)G_T4E'_
M  TW\5?^C$_VL?\ P;?LF?\ T4E?7]% 'R!_PTW\5?\ HQ/]K'_P;?LF?_12
M4?\ #3?Q5_Z,3_:Q_P#!M^R9_P#125]?T4 ?('_#3?Q5_P"C$_VL?_!M^R9_
M]%)1_P --_%7_HQ/]K'_ ,&W[)G_ -%)7U_10!\@?\--_%7_ *,3_:Q_\&W[
M)G_T4E'_  TW\5?^C$_VL?\ P;?LF?\ T4E?7]% 'R!_PTW\5?\ HQ/]K'_P
M;?LF?_124?\ #3?Q5_Z,3_:Q_P#!M^R9_P#125]?T4 ?('_#3?Q5_P"C$_VL
M?_!M^R9_]%)1_P --_%7_HQ/]K'_ ,&W[)G_ -%)7U_10!\@?\--_%7_ *,3
M_:Q_\&W[)G_T4E'_  TW\5?^C$_VL?\ P;?LF?\ T4E?7]% 'R!_PTW\5?\
MHQ/]K'_P;?LF?_124?\ #3?Q5_Z,3_:Q_P#!M^R9_P#125]?T4 ?('_#3?Q5
M_P"C$_VL?_!M^R9_]%)1_P --_%7_HQ/]K'_ ,&W[)G_ -%)7U_10!\@?\--
M_%7_ *,3_:Q_\&W[)G_T4E'_  TW\5?^C$_VL?\ P;?LF?\ T4E?7]% 'R!_
MPTW\5?\ HQ/]K'_P;?LF?_124?\ #3?Q5_Z,3_:Q_P#!M^R9_P#125]?T4 ?
M('_#3?Q5_P"C$_VL?_!M^R9_]%)1_P --_%7_HQ/]K'_ ,&W[)G_ -%)7U_1
M0!\@?\--_%7_ *,3_:Q_\&W[)G_T4E'_  TW\5?^C$_VL?\ P;?LF?\ T4E?
M7]% 'R!_PTW\5?\ HQ/]K'_P;?LF?_124?\ #3?Q5_Z,3_:Q_P#!M^R9_P#1
M25]?T4 ?('_#3?Q5_P"C$_VL?_!M^R9_]%)1_P --_%7_HQ/]K'_ ,&W[)G_
M -%)7U_10!\@?\--_%7_ *,3_:Q_\&W[)G_T4E'_  TW\5?^C$_VL?\ P;?L
MF?\ T4E?7]% 'R!_PTW\5?\ HQ/]K'_P;?LF?_124?\ #3?Q5_Z,3_:Q_P#!
MM^R9_P#125]?T4 ?('_#3?Q5_P"C$_VL?_!M^R9_]%)1_P --_%7_HQ/]K'_
M ,&W[)G_ -%)7U_10!\@?\--_%7_ *,3_:Q_\&W[)G_T4E:^@_M$?$O6=7L]
M,O?V,/VF_#-K=?:/.UW7-4_9B?2K#R;6:XC^UIH?[1^MZJWVJ2)+.#[)I=T1
M<W$)G\FV$UQ#]444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5%//%;0R7%Q+'#!#&\LTTKK'%%%$C22RR.Q"HD<:L[LQ"JJDD@"I:Y'X@>%(
M_'G@/QKX'EO[O2HO&?A+Q)X4DU2P8I?:9'XBT:]T=]0LG!4I=V:WAN+=P05F
MC0Y&,@ _%36?VD_^"F/[=.MZE?\ _!/*Z_9\_9N_9GM+_4=-\,_M"_'KPKK_
M ,5/B7\6[;3;VZTQ_''@3X7Z;?Z/X7\,?#S4;RTF;PK=^,-2O->\4Z4(/$$.
MG:;IU[:1R_EE^S3^V#_P6Z^+_P#P4+_:G_8AT?\ ;._9P\9:=^RQKOACPKX@
M^+>M_LC:?9>'?%'BW7=&BU?5= L-!\,>.='NM/'AH2/:W5RVLRR3SQ$>4@R%
M_<3_ ()\? SX[_\ !._]BV]\(_M9?%'X=?$?_A0WP]U^Y;QUX%TS4M"T>7X=
M?#32]1F\.3ZE;:Q';W":O8^"-)L;?6YUCCMYKZWEFB,FYII/R._X-AO!&L?$
M+X>_'3]L_P 8V-Q'XN_:P^/'Q=^/&HW%Y))<3&U\6^+]2M?#T"32EG%O9V%K
M=P6\:MY<4/EI&H11D ^5OVI/@]\?F_X*^?#']FSXW?M!7OQU\2_M3_"K2?CM
M^U[X4\"Z1K'PT^#%S\,O@^MY\,O@C\)M+^']MXHUZ]L]!UWQ5J-SK_Q#-YKU
MQ<>-P=*M[[%I#+!+_4+^R;^P%^PI^R==ZOJG[+_P(^#_ ,)?%>KK86?CJZ^&
M=C9Z==:CJNC0RA+36H+2[G\J;2WU"\\JR=81:->3-Y*O,Y;^8#PUHOBW]MS_
M (+D_P#!3/XS/XNO?!/P)^!=KX3_ &;=?\=>#]:N]&\92>#_ ((>$)O$WQ'\
M->&/%-DZW'@_3M5O@^H^)-:TF>VUXM';6NC7=A/=75W#\Y_\$E_VAK7_ ()X
M?\$U_P!O3_@I1->>(M2\&:Y\3/BMXN^ '@;Q9K_B+5X=:UCQ5XE3X9? [0KR
MZUN[OM4OAJNI6=MJ^IZE<S37U_IJ237$[,PE4 _OGO?$WAS3=3L]%U'Q!HEA
MK.H0R7%AI-[JMC:ZG?01%A+-9V$\Z7=U%&58/)!#(BE6#$$&ME65U#(P96 *
MLI!!!&001P01R*_A-^&'[$?QA_X*%>,?V*OC#H&G?$&;XM_#7QU9?'S]J[]N
MK7M0\1>&]6^+7B_6-$CO)/@5\)=*O98+NX^'FC:W=PVSS)IND^#_  CX?T:V
MT#24U*>\NI7_ +A? 6AZCX:\'^'=#U:^?4M1TW2[:UO+UV+-/.D:B1BS$LV&
MRJD\X'- 'QM_P4:_;Z^'7_!.[]GN;XQ>+]%O_'OC;Q3XIT+X8? [X/:#>6]G
MXG^,/Q@\87!LO"G@O2)YTE6QM9)PU]K^MR6\\&B:-:W5V\-Q<?9;2Y^,/A+J
M_P#P6U\9^/?@I\5M?\4?L>:C\!/'L&I3?%[X1Z)X2\8>$_&7PB/V":[T<^!/
M&NH:WX@'Q0M1?"WT;4;O5K7PY)<MY]_9Z9:VIC9?S7_X*?ZU>?M=?\%Y/V*?
MV5K%KZ_\#?L9?!O6OV@O&FG@17.B/\3?BQ??\([X/CN44LT6J66@VEI?VGFJ
MIA+K+&3OP/ZTO#.D0:!X?T;1;9!'#IFFVEI'&H&%6&%4[#G)!)P.IH O6DT\
M>G03ZJT%O<1VB2Z@WF*MO Z1;[AS(Y"I#'AV+N0%12S' -4M&\3^&O$<)N?#
MWB'0]>MQ+) ;C1=6L-4@$\) FA,MC<3QB6(D"2,L'0D!@#7\TO[67[1FH_MU
M_P#!5_6/^";,.L:G;_LS?LM_#_P7XN^.WA+1-8O-+MOCA\:?B;-%=^$_"/CR
M?2YK6^O_ (:?#SPRD^KWWA$7,5GXA\7/ ^MB\TVPM[6ORP^&OB/PW_P2I_X+
M>_\ !1_P?\'M4UKPE^Q9\&OV?? O[0GCSX=VFM:C<>"_"OB:_P#"/A/Q3J&E
MZ+9WUS<VFAW&M3:GXEL-/M(MBI'+# 0\&FPK" ?W6:MXC\/: UBFNZ[HVBOJ
MES]CTQ-6U2QTUM1N_E_T6Q6\GA-W<_.O[BW$DOS+\O(SJQ2Q3(LD,B2QM]UX
MV#J>W#*2#[^E?Y^5G\.OC5_P7*^!6B>-Y_!GB_7?VG/CW\:/#?Q8U+]HR>\\
M1:!\/OV)_P!G[0?%UWJ7A/X1?!R8W%HFK>+=2\"QV%I<Z1X9L;A-0\1ZIJOB
MKQ=KTCPVRQ^I?\%9?A[^U;\"?"W[.G[+GQ;^,&M>,?C%^VO^U'KOP\^&GCGP
MY\1/']O8_!']E'P@GARYAB\-^%!=:=X;TSXN76E7,UIKOB&&WO+B>ZDN;Y-3
MGFGC%H ?W67&MZ-:>5]JU;3;8S7'V2$3WUM"9KKRGG^RPB253+<^3%)+Y$>Z
M7RXW?9M5B-%'21%DC971U#(Z$,K*1D,K#(((Y!!K^9O]IW]F/X;6?@3_ ()9
M?LA?#_4/$]O\3_!?QXT#]I#2WTSQ/KM[K'A+X-?##PEKEEXRUGQ1/+J,M[=Z
M9XVU[6?"_@VTEUJ2<:OJ^J:D]H\LME>JO]('@W39](\*Z!IMT[R7-GI5E!.\
MC%W,B0J&WL22S Y!)ZT ?F]_P4N_X*/V'[#FE_![X;?#SP?8?%W]K/\ :>\6
MW/@C]GSX1WNK/I&CR'38([KQ=\3/B'J=K'<7^C_#3X?Z=-'?ZY<V<!O]5N)+
M?2-,:.::>[L>%_9]L_\ @L5;?'#2M8^.?CW]E7XG?LR^+/!-OKZS^!O!'B;X
M7?$CP+XR>[M0_A7_ (1_4];\56GB/PW/92W,]EKUQK::HJP(;VWMYG%N_P".
MUA=7'[='_!R)^T'XJD>YU3X=_L,?#3P)^S#X,@N8P]A:>,_$3GQC\3KS3I$+
M1?:+>\_M33;R3B7[-?PPOPA _L%@B2"&*",!4@BCA10,!4C144 =  H  '04
M .WA(O,E9$"IOD8L B!5R[%R0H5<$EB0 !DX%<=I'Q(^'OB#6)_#V@^._!NN
M:_:6ZW=WH>C^)]$U36+2T>X-HEU<Z;8WL]Y!;-= VPGEA2(W ,(<R#;7X+>/
M/BG;?\%5/VROVA_V1QXD\3Z1^Q9^RAK=M\*?BG8>#_%.K^#7^//QWAT^+Q#\
M0K/Q9XH\-7NG:X/A=\'=*DL-%;PQ9ZG8VOBCQC>SZAK4EWI&EV5HWXC_ /!&
M3]C[Q;\83^WC\4?V%O&MM^SYI?Q-_:^U#PE\-O$%WJ'B>:;2?V5/A+\2%TO6
M_#7AKQ/;2ZKXBTGQ'XTT&;78]*\1VT[S:;K2B\AFMI$BN+< _O1FFAMT,D\L
M<,8(!DE=8T!/0%G(&3V&<GM2&> -&AFB#S#="AD0-*HP2T8+9< $'*YX(K^'
MC_@F1X3'[7?_  5B_:Y^(]]J'B^P^%_['_Q3\1_L^_"[PA>^/?'&MG4-?\ S
MZPGQ$^)WC"^USQ!?R^+?%7B)]/GL;"_U7>-(TB^^SVT,<C32O[)_P;W?$3XS
M?'_]H3]O#]KWXQ_&36]8\)>-/VD/BEJ.FZ+KOB>[G\.>#O!7PRN;[1+!%M+N
MY.EZ#I^E:$+&R0V@BM&TS2HKJ<[R[T ?V+VFL:3J$LL-AJ>GWLL$LT$\=I>6
M]R\,]LYBN8)5AD<QS6\@,<T3XDB<%)%5ABOFW]J[]J?PK^RQX'T36]0\/:Y\
M0OB!X_\ $D'@7X/_  C\)264?BWXF^.KRTN;^/1]/N-1EAT[1=&TK3;.\USQ
M;XLU:6+2/"WAZQO-3O6D=;:TNOS)_P""._PFM=%E_:#^,G@P^*K'X2_'G]IG
M]H/XV_"G1O$FH:G=M;?#?Q]XT+>%]3M8M5N;BYM;#Q<^GZCXQTFV9E$>CZW8
M21(L$L0KKOV]?@_^TYKO_!0_]@GXS?#'X6W7Q.^!_A'X<_M$_#[XG:A::GI\
M+?"KQ%XU/@75-!\83:3>7$5Q>0>(M/\ #=[X2>ZTV&YN;>*>>VD6.&\)< ^
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M!* @-C()!P<5HT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/PSU+49M%\-NL6OMJ6E:1!>P7$HG\WZ=_P"$<_X*"?\ 16_V2?\ PQOQ9_\
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M?Q!+/%;77PN7XQV\<%]H'PWB5IDTB+3[F&#7;C4"WVG6_$$4%_>HL=I96]N
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M_6_^"<TOC'Q/^U;=>./C#<ZWX,_;7/P;?X^^'K/PE_9NM7.G_"[PEI_A#6?
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M,"R\._"_P3\(-=^,^K>(_"/PA^+?QN^/'PGNCX6M[3Q!'\8?BKK/C_7O"7Q
M^)5]-K5_;>.]:^$&I_$76K_PLL5GH-MJVJ6^EZEK<<TFGP0@ ]OLO^"CO[+>
MJ:3X UC3_$/C2ZM/BCI?[0FL^" GPV\;0RZQIW[+HU-?C/=.+G1X$TR#PU/I
M-U9VMUJTEE::Y=M;0Z//>_:82_QI\<?^"E7B[Q[^S-^RW\1/V</#7Q<^"_Q$
M_:>_:!^&/@_PMH?Q8^"E[=>+%^$,UEJ'Q)^*7CG3_!.KV%R?%FD6'P5T34-<
ML-2\*R7B0:[JN@Z<+V2=IK:2E;_\$=-<'P=F^&EU^T[+#JFF?L,R_L1> ]7T
M7X1Z9I6C>!]$UWQ=I?B/XE?$"QTA_%]YJNH>(_C%8Z4NB_$=;WQ&9]0CN[JY
MTK4=)4K:U]&?$[]A;XN_$?QUX1\?I\?_  CX7U;X8_LH_%;]GCX2:?X?^$%W
M:Z#\./&OQ@M]"T;Q#\9="T^3XBS3+JFD^$/#]AX4\/>'6O1!::>LDDNJ2-<W
M$<@!]Q? WXV_#?\ :.^$W@?XW_"'7F\3_#;XBZ.=<\*:Z^G:CI,M]8)>76GS
M>?IFKVMEJ=A<VU]97=I<VM]:07$,\$B.@(R?A'Q%_P % )/%O[3?QQ_9#^!V
MK?"33_VAO@'<> ;Z7X/_ !HN]9T/QG\</"?B71M%\3^)/$WPEC@U?0E_X1WP
M[HVIW6G0>);>S\:17/B;1]2L+S1;&U2&[G]S_9!^#/Q:_9]\/7_P.U*7X?6W
M[/OPF\!?"3X<_L\KX<T&ZTOQG=_\(OX*BT_XB^*?&I?7]9TZY7Q'XL']J:3"
MD5AJ D;5)M16=;JVG?QGQ;_P3RU+XL:[\&/'/QG^+]CXN^*W[.>A?%./X/\
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MM/[0M%EFBC627R]RD _/_P"!O[<_Q ^*.F^*_B+XP^''PG^'7P*\'_'SQY\
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M&O?$+4O ?BKPI9^.-*;Q3X:^)GCWQ#=>,O$"Z?J7AJ_L=>T_1KF&[NQIX\P
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M2.U^!.A_$C^SIM3\2>/]>OY[2_\ %KZ5#I?_  BD.JV6A6TAUZ[6RL>6T/\
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MEX:\N>=/["MKB/3 L\R_9=LC@@'XZ>)_^"E7[2?AGX ZI^USIWP[\'_$_P"
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>atnf-20241227.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWaiAaaPtyJ1xaYkxuG93fXmq7y0vQg4AdCvb2s1GsXgF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ATNF="http://180life.com/20241227" elementFormDefault="qualified" targetNamespace="http://180life.com/20241227">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://180life.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20241227_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20241227_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20241227_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="ATNF_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>atnf-20241227_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180life.com/role/Cover" xlink:href="atnf-20241227.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://180life.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnf-20241227.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnf-20241227.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>atnf-20241227_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20241227.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_CommonStockParValue0.0001PerShareMember" xlink:to="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20241227.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>atnf-20241227_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180life.com/role/Cover" xlink:href="atnf-20241227.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://180life.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnf-20241227.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnf-20241227.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45725778916000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 27, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 27,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">180 LIFE SCIENCES CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-1890354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 El Camino Real<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Bldg. 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">507-0669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase shares of Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNFW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MG9AM;_(V%(;_BI5-TR:UX(270@=(E-(-/7U:UK!5VC>3&+":Q)GME/;?[SA
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( ,.#GEGB09)4[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,.#GEF97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ PX.>
M6=X[O;V[!   <Q0  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( ,.#GEG@]#J)J@(  # ,   -
M      "  ?X,  !X;"]S='EL97,N>&UL4$L! A0#%     @ PX.>69>*NQS
M    $P(   L              ( !TP\  %]R96QS+RYR96QS4$L! A0#%
M  @ PX.>6:K$(A8S 0  (@(   \              ( !O!   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( ,.#GEDD'INBK0   /@!   :
M  "  1P2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M ,.#GEEED'F2&0$  ,\#   3              "  0$3  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  $L4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0226200-8k_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://180life.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnf-20241227.xsd</File>
    <File>atnf-20241227_def.xml</File>
    <File>atnf-20241227_lab.xml</File>
    <File>atnf-20241227_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0226200-8k_180life.htm">ea0226200-8k_180life.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0226200-8k_180life.htm": {
   "nsprefix": "ATNF",
   "nsuri": "http://180life.com/20241227",
   "dts": {
    "schema": {
     "local": [
      "atnf-20241227.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "atnf-20241227_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnf-20241227_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnf-20241227_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0226200-8k_180life.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://180life.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-27",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0226200-8k_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-27",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0226200-8k_180life.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "auth_ref": []
    },
    "ATNF_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180life.com/20241227",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180life.com/20241227",
     "localname": "WarrantsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://180life.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001213900-24-113500-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-113500-xbrl.zip
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MQ-LP0]R?.YZHZ.F5C*BJ0_ZA=2O8MX*&Z/_9+?W3%:;4/!!$K%;K+]JW0@(
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M/NJ*[LLG5Y7NC=;JN"A R3*I]X?>08"Z^GM]+CEN?IE_!*./_ U02P,$%
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M!&"S#H4A"H@*NS, BUR,E!H)N1<P[GB\QOQY&D<=0T53Z!8-R&B=#5,5$!R
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M0/, 2 U]B#A!)CNATH$^V9J2:"O&Q^?Q9#Z+LT82.KO$V9@$F"M')&-_$&P
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M;6S5G5MSVC@4Q]]W9K^#EWTF7-*]-&UV)Z6AP_22;*#M[KYTA"U $R$QDIS
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MPUTTW4JD2L@#:!H8M"8QM&="R";I'J'5?BC;UW$UY2I/53G!\]?O>=U7/9Q
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MI7#.X!9T8IXB)4BPU223EOS -IIH1 %7@?^T$L-?1\A^.EC6#0):C[X'M,*
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M-=452-3R#[@$JUDMT7:@+72WLI-VHX.:5W]S[2ZJCDTT5\;+,S!92/XVL>K
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MZS[@8\<A\=G<8\[VR ^TW;SP]82O=T]*'<E3ZM6\=C>N;M,[Z,0B _\ZEM(
MTCP-O+)%X;*I+PX:-S22')A$AQ99Y.Q$]\RRRB6GK=9 .4L=&:[!J)$<BHR4
M]2L]+)-*.J0B,\/7,#9-!2+> /YZD*@N 2/35^4\GANXCM_A<L&M8TQ-<J02
M&"<R#LQWN\I,GL9?CW9-$D 3\.%_00*SZQZC#F.#/T^I)!<:G="EZ7TI;8F)
M;Z5Z APHC;,/VRBY_^^+S_LK;==-,D1^^IXA$F:(_/0]0^3FI,S__R4YSTF*
M=K.!M' RQ5J[U&=."J9 _)=&_B^\! S*_H.QC.8,.@ :CYQ[0=D/D@DB(("4
MJ=J,[7X#G/>\]^JHKP[Z1T=G)[V#P?&;OS_8>4!_G_0.#\W?GSR[JV1<3?&G
M.S_8NXT5-/&\!/(V_WI 5/GB_-0,0')N%*=F)4#Z#PSEGA_:N<,_[8?JX!U.
M_?CO#_9KL!54@#*)9TFZ?+9ZO@]>_H8!U:I8P)DOX:3+R): P%CP/Z>W/5/O
M!W?Q^L_<""&9#JWMU4LF[3>G[WX]44='!^@B_A-NE#QZ-055:PMT)A1C67Y5
MQ/,_0$&OEL]J8"CM2]JSM^EZD?>P?*A.89+E5/VF=1%_YB[8!?.E?++SPX/5
M&\._>W2SGSW^X0_L&@O/]BT+A]G?A7%N83-:E]3^X6>OZAR+%E>1P\N#?.L7
M'8^Y70NF1)-4>04:)@@1?V7P'^30-3%AF?^?FI_7Z?+1'Z&D59>O1DE/?F@J
M)L]5HU[QLZ<"YFW/^1MX&NQO>!; .GT>_=[E#MWEKNSO[("67'Q0O4N=+?0]
MW06O5.P]7J>]O7NZ$;U*+.QGZA\Q_O(LT1<8N7C#!6P\F0..9]S3/>JC9Q7T
M^9*VYK]GJ'U=%//M43Z["[7KYBOZ8TK9Y],,E4,*=D*/X6 Q;(_U469#/NUD
MOO0*K-L<C,^RLIE-U)SOV1^FLW UWY3F\//^*L7!NC;0TV9-U4]3)CRCX<9[
MUFHWWYGUM/MTAZ=[E$RT*D>4/XY J'"EZZ;4G3"OSS =OOZNKN3"7WEWOH ,
M +ORUBS*NU5[T5J%(9-"_8,*;/[,!V;YUEW;)#>?R1^WLV]U.F2/J\\GZPY"
MZ7!7_#FHYL%7T!'9U[#:A7*7XP\(+'"F#JC!<]^V07_'Z71?D G<,WVGYJS;
M^:).#?%GH#MCM=K:X7.\TTMXG8?OVQ3TH!VR8GAF%,,#5@S;+M ?6TV+ZG#'
MGI\=U4_5 ?P\R]6IQLS[5^GX8EL]@A\M$K"']L@[E.:JEV(]Z$%/_?QH?^?)
MMZ^?B8T^1'FV_3O)L_^>)A?3&9;Y2<IPW6"_YAP_D9%]L7897Q6DXDNFB)S9
M)"\*D?O](CBM=[3TJBQ?214\)75^\12-@0G*%?EBCD$Y<HX89K*^5N<F7OK*
MG03?;YS$LB*GY.GWG)(PI^3I]YR2;S$]ZM5+T!3[QX>_OE4]=N!\^1F 7C8X
M/NR_/1Z\'AST*"?SY/3=;X,S^-<9AYON;&+?:'KJH+U44UL($P(EJ+/-#?R-
ME!DUTC>Y6A73?CK4M.!Q6\<JC_G@NS$G=?(TI,VDRRMBR!37%=&KU8E6=SZK
M=4BG&FZ+ &"@$K@&"#:9$M&3F5\"L+[F+\&*-U>IVX9/R(FY<2FIX>6S^T5I
MNZ;K7LX9\? 3/((Z<EZX=U1 8^!C.KI#(<@C0D=,L.$(]^7RBM=:2M4,TF)5
MP$$P!!P519>,@&A:U.LX$V ) W.R^[BEAV:/D25W?][?Y^HDIA_*T#</[NVT
M/!AV)Z8W/,(B8?N*38O6C$GV:5Z6N#9" <0U,K9RY##D<%E8G@3;(, :I8<U
M037'##)7QVWR2IX,4ATVZ)774J-2"BUNAL!)6,(F0*)8Q"A%E(A!=YE8Q!HN
MH\%BFZ!WF?:+3;G$/C+@J![.;*,A7F3+0IA\+.+$]=M#[8?M[G##A%$E*$0.
MD]7T2F ,FP5!B&(Q20VU<8. ,1RV?3R?@ZVVR26@ML,K0@.8OM9<M<LHZ7")
M$BELMXCSMNBP*R$>+\-DD:ZOS9+2X+["(BX*6+K*] 5<0E)U$**/87W- 4O5
M"%:XEZ,B&5I %4LCE/#.'/"6VT'>',OYZ_*G/=L2DMNVF4*F6E5-2YU^9CO,
M(2$R2J<%/V(8RYG\E,10&\)D'1?80FLV6T(B.HG#>C?<4=!GI7M VTQ-8;IA
MI&U=[DR3/+,&BT+@ED$*02?:I,5,#EDXEDO.N*ADK"=X'U=B5CH(#F;:M@%B
M9V/#%2T,Z3WSF!=MD3A]]F8P5'&(9IEOQ7BA(X$"1063\-.#\4P)JZGX]$^H
MMH:2<3PU7WCSJ=<YPBHK4J2S#$!&:T"ER<1_17NML== U&)?28D0Z#W<.II*
M'(&)$<@#SL[@]FH?Z@2[B)>"N3O15-!'A6?E'&&.B+<NW3PL7!#.CLJ(I):7
M<89NH)MMJX$LE^JIHRYQA86SA,LJG3?Q4@IP$Q7W(?228 S+YIMIF0.;QTD=
M>R(LK*(?VM(H$%F"L.OA U=5:D"IY/XXDD: %JDN]0K6O5>3/.%7.%Q??$_4
MS3%NA)->EZ#K:QZFF."#+3*/1O#-4S!1[ZD@V&]K#VW*ZG*?@];OF>WX*3L/
M7$]S5;Q1Y)(Z]ANC\5PG.HCG=LH.7R<+>\F@DHO<)ZX<L,I==?[^LQSO(SG>
MP82!*QG?#XD_K&WQ!"M(W$46H)]T(#K &3N$<M3[L)U,VV^G<3%#)$:&I Z
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MUEU![(>OWAV^IZJN7\[?'KW\?U!+ P04    " ##@YY9=#ILI)FR   DMP,
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ME*E]NKL_^?41M=K_#;.[6!1E ?JG-\$XHZA/;F1CPS1G(%/FH$#-0)E*0/Y
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MOG9XD!P$-KTIDMUTL+>'RZ4JBYW_]%[5=? (3B9^]MDT'X\<^;S)16-"=KQ
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MYP6TV6[ 7%QZ)NDOAT=>N%],*8KZ1;Q@M_F_A:+36=:&)M3^G%E"TXCAR@E
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M[\5 7JJ1\F@0!\ XE=KB,$?3G)*Z\VXKOEG#SS#RGLW(RXDR9BFU=0PBK<5
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M-8V_6[MB=NIJ=&@ /G+]E"GI\\I""$S-U*S##8D'Q,TEKI%%%:A$7EO4I5_
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M>6Y2.E8:%AJ+*>KGL!YFU091T^'I1<^&O*[U2XG&7A3TS)7\PW>RI1FT +<
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M8MQS*=&Z#8Q.Q8>%#5!Y'"6T4'/Q=T,UR*X_&YZV9]0+ !O*,\<,WPOHWN9
M-I@^-NA#!2:32@LH7Q8<<5K@<G2XISH$U@D^$"G ",9/-#NA9U('$ )EN1_
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M5.@VZKP$6;WPB5GWY(R&ZW&7&^R I_UP,LZ]U1^C_$QN&LSOK#P/E(! .5S
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M[545ZQ,M!AIE?U<LAV]>+(3M,N(\HXW;]Y[!Q0=O!ETCG^N<*KLW)1 Z@U.
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MXHZR*"W?0)%/#/U1_EQP6>4.QCVTD$&%")/@KF@+[X@6;=?WY>1&F$Q;KLZ
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MC![H\FT"(U 7V]J_?'57^_2AS#O_L$N69V)*$W'K1(<O<UEY$[*[,86\0@&
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M$1A^G3M("#A%(@_;CQ]\=_+NZ/O%Q7=?T7]W<+=MYXYG+$!%ZX)W'HEKT :
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M(PT[B&X;4ESE^7G VEZ)ZH9-@";:@USI55DOEMA@ Z#:1$="R"2Y*0&X'D9
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MZT6X'^V"GM'5'895/2MN&MGDLXFN%;Z>;'*0!^LVZTW.UJQ$SZ#ZJUDJG@T
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M!L-F5X<4U5JS-'FR"UZ.IU&/RW-@3GTSJQOG'JH%I4*1!)PSDNTARA-/M60
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M)!_47UT!-1=%!(V9!7I6W1^>J7HY<6])]5QO&X4M^.3>LV0(V;5?^0UETU]
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M0^]F"3\R![9;@J>,\8!()Y7<SP)NU7A8S"<-2$?A!Q)<TT:;*.02NH6T%P@
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MA?\D/L."UATV>1IH5F;.9U9ZQ(,*,0L#DM!'5$7"VGD=K4XD<D=L[A[]PL-
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M]/. 5G-X=GHZH'=4JPD.SD[[P:OCHP%<?O&SK/CM*5'QC([ R1D0D&X*-SD
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M;TU&*3G>,7 ^2-YH-(KG%7)QG77 $!B]S_);<+JGK-@CM(?%S8>?,H\+]Y"
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M0@1GP'X(HBU;R_O-B?0W=Z"#2*D+%HZ6]6$KT"DU5 F5.LFIHWY:,IJI#1]
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M;:.%H"[T+!+3=AE<:)K/NS7SRP C?@D(VF+9:UVRNQR,%81!&I-63),1-I1
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M;2K9#>Y3%Y>RT=.NO?^6IQ>698'04 LKWV-&*8K4E&Y#F3C2I-!E;E,@C;I
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MY2YTT:.#LZ-_O,0_O+YZ<_+R_P-02P,$%     @ PX.>6<4L Z"^"P  3"T
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M\64*LB;XIBX7?>BQF=+<<COVL"\Z JZ!>%[ISKI>^O!,S&6=W24ELEG0S<M
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M_N)B+$WU]4V/_H*CG'WZ-K3]>C1]B_I74$L#!!0    ( ,.#GED]" BR[Q,
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MOQH@_XP _6L#_PU02P$"% ,4    " ##@YY96H6A+<H#  #2#@  $0
M        @ $     871N9BTR,#(T,3(R-RYX<V102P$"% ,4    " ##@YY9
M0ME ,/P(  "%:   %0              @ 'Y P  871N9BTR,#(T,3(R-U]D
M968N>&UL4$L! A0#%     @ PX.>6;Q[.-?Q"P  %)   !4
M ( !* T  &%T;F8M,C R-#$R,C=?;&%B+GAM;%!+ 0(4 Q0    ( ,.#GEGU
MF9S-0@@  !]C   5              "  4P9  !A=&YF+3(P,C0Q,C(W7W!R
M92YX;6Q02P$"% ,4    " ##@YY90"IC(5@<  !_I@  &
M@ '!(0  96$P,C(V,C P+3AK7S$X,&QI9F4N:'1M4$L! A0#%     @ PX.>
M604+3[2?,P  @_P  !P              ( !3SX  &5A,#(R-C(P,# Q97@Q
M+3%?,3@P;&EF92YH=&U02P$"% ,4    " ##@YY9=#ILI)FR   DMP, '0
M            @ $H<@  96$P,C(V,C P,#%E>#$P+3%?,3@P;&EF92YH=&U0
M2P$"% ,4    " ##@YY97ORAF0M#  !L;0$ '               @ '\) $
M96$P,C(V,C P,#%E>#0M,5\Q.#!L:69E+FAT;5!+ 0(4 Q0    ( ,.#GEG%
M+ .@O@L  $PM   <              "  4%H 0!E83 R,C8R,# P,65X-2TQ
M7S$X,&QI9F4N:'1M4$L! A0#%     @ PX.>63T("++O$P  =$   !T
M         ( !.70! &5A,#(R-C(P,# Q97@Y.2TQ7S$X,&QI9F4N:'1M4$L%
3!@     *  H P@(  &.( 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>ea0226200-8k_180life_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ATNF="http://180life.com/20241227"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atnf-20241227.xsd" xlink:type="simple"/>
    <context id="AsOf2024-12-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="From2024-12-272024-12-27_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="From2024-12-272024-12-27_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-12-27" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-12-27" id="Fact000004">0001690080</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-12-27" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-12-27" id="Fact000010">2024-12-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-12-27" id="Fact000011">180 LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-12-27" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-12-27" id="Fact000013">001-38105</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-12-27" id="Fact000014">90-1890354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-12-27" id="Fact000015">3000 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-12-27" id="Fact000016">Bldg. 4</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="AsOf2024-12-27" id="Fact000017">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-12-27" id="Fact000018">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-12-27" id="Fact000019">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-12-27" id="Fact000020">94306</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-12-27" id="Fact000021">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-12-27" id="Fact000022">507-0669</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-12-27" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-12-27" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-12-27" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-12-27" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2024-12-272024-12-27_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000027">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-12-272024-12-27_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000028">ATNF</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-12-272024-12-27_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-12-272024-12-27_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000030">Warrants to purchase shares of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-12-272024-12-27_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000031">ATNFW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-12-272024-12-27_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-12-27" id="Fact000033">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
